DATAID,SMILES,Name,IUPAC,StdInChl,StdInChIKey,Pharmacophore,Core,ResearchStage,TherapeuticUsage,logP_exp,logD_exp,logS_exp,KineticSolubility,ThermodynamicSolubility,RecruitingProtein_Affinity,IsActive,ModeOfAction,PrimaryTarget,PrimaryTargetDegInfo,DegronType,SecondaryTarget,SecondaryTargetDegInfo,RecruitingProtein,RecruitingProtein_UniProtID,AntiCellProliferation,TernaryEC50,PK,ADMET_profile,SafetyPharmacology,InVivoPD,SourceAddress_Website,PDB,glueCodeInPDB,CryoEM,Formula,MolWeight,ExactMass,clogP,logS,tPSA,HBACount,HBDCount,RotatableBondCount,Rings,AliphaticRings,AromaticRings,AliphaticHeteroRings,AromaticHeteroRings,HeavyAtoms,HeteroAtoms,SpiroAtoms,BridgeheadAtoms
1,[2H]C([2H])([2H])OC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,36,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-(trideuteriomethoxy)naphthalene-2-carboxamide","InChI=1S/C25H21N3O5/c1-33-19-6-4-14-10-16(3-2-15(14)12-19)23(30)26-18-5-7-20-17(11-18)13-28(25(20)32)21-8-9-22(29)27-24(21)31/h2-7,10-12,21H,8-9,13H2,1H3,(H,26,30)(H,27,29,31)/i1D3",JGWFFKIYBDZDFI-FIBGUPNXSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,70% degradation at 100 nM,G-loop_beta-hairpin,CK1α,62% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg
; human: t1/2 = 4.8 min; CLint = 289.7 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C25H21N3O5,446.48,446.1670,2.86,-4.86,104.81,8,2,5,5,2,3,2,0,33,8,0,0
90,CC(C)(C)CC(C)(C)NC1=C(C2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)N=C2C=CC=CN12,Compound 12,"2-(2,6-dioxopiperidin-3-yl)-5-[3-(2,4,4-trimethylpentan-2-ylamino)imidazo[1,2-a]pyridin-2-yl]isoindole-1,3-dione","InChI=1S/C28H31N5O4/c1-27(2,3)15-28(4,5)31-23-22(29-20-8-6-7-13-32(20)23)16-9-10-17-18(14-16)26(37)33(25(17)36)19-11-12-21(34)30-24(19)35/h6-10,13-14,19,31H,11-12,15H2,1-5H3,(H,30,34,35)",CGKKMJUNHRRYMQ-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 22 nM; CK1α DC50: 170 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 > 10000 nM;
Cell: SUDHL5; EC50 = 5800 nM;
Cell: Molm14; EC50 > 10000 nM;
Cell: NB-4; EC50 > 10000 nM;
Cell: LoVo; EC50 > 10000 nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C28H31N5O4,501.59,501.2376,4.03,-5.90,112.88,9,2,5,5,2,3,2,2,37,9,0,0
91,CC(C)(C)CC(C)(C)NC1=C(C2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)N=C2C=CC=CN12,Compound 11,"3-[3-oxo-6-[3-(2,4,4-trimethylpentan-2-ylamino)imidazo[1,2-a]pyridin-2-yl]-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C28H33N5O3/c1-27(2,3)16-28(4,5)31-24-23(29-21-8-6-7-13-32(21)24)17-9-10-19-18(14-17)15-33(26(19)36)20-11-12-22(34)30-25(20)35/h6-10,13-14,20,31H,11-12,15-16H2,1-5H3,(H,30,34,35)",URPATGFIHKJSDH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 2.0 nM; CK1α DC50: 9.1 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 = 900 nM;
Cell: SUDHL5; EC50 = 41 nM;
Cell: Molm14; EC50 = 420 nM;
Cell: NB-4; EC50 = 140 nM;
Cell: LoVo; EC50 = 1000 nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C28H33N5O3,487.60,487.2583,4.39,-6.22,95.81,8,2,5,5,2,3,2,2,36,8,0,0
98,CC(C)(C)NC1=C(C2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)N=C2C=CC=CN12,Compound 4,"5-[3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione","InChI=1S/C24H23N5O4/c1-24(2,3)27-20-19(25-17-6-4-5-11-28(17)20)13-7-8-14-15(12-13)23(33)29(22(14)32)16-9-10-18(30)26-21(16)31/h4-8,11-12,16,27H,9-10H2,1-3H3,(H,26,30,31)",IEPVLXVJCUHDAW-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 8.6 nM; CK1α DC50: 12 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 > 10000 nM;
Cell: SUDHL5; EC50 = 1600 nM;
Cell: Molm14; EC50 = 2000 nM;
Cell: NB-4; EC50 = 1000 nM;
Cell: LoVo; EC50 = 420 nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C24H23N5O4,445.48,445.1750,2.61,-4.66,112.88,9,2,3,5,2,3,2,2,33,9,0,0
99,CC(C)(C)NC1=C(C2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)N=C2C=CC=CN12,Compound 1,"3-[6-[3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C24H25N5O3/c1-24(2,3)27-21-20(25-18-6-4-5-11-28(18)21)14-7-8-16-15(12-14)13-29(23(16)32)17-9-10-19(30)26-22(17)31/h4-8,11-12,17,27H,9-10,13H2,1-3H3,(H,26,30,31)",IFLAYQIAAFCPNM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 3.1 nM; CK1α DC50: 1.1 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,IKZF2,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 = 49 nM;
Cell: SUDHL5; EC50 = 15 nM;
Cell: Molm14; EC50 = 570 nM;
Cell: NB-4; EC50 = 400 nM;
Cell:LoVo; EC50 = 20 nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C24H25N5O3,431.50,431.1957,2.97,-4.98,95.81,8,2,3,5,2,3,2,2,32,8,0,0
164,CC(C)OC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,38,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-propan-2-yloxynaphthalene-2-carboxamide","InChI=1S/C27H25N3O5/c1-15(2)35-21-7-5-16-11-18(4-3-17(16)13-21)25(32)28-20-6-8-22-19(12-20)14-30(27(22)34)23-9-10-24(31)29-26(23)33/h3-8,11-13,15,23H,9-10,14H2,1-2H3,(H,28,32)(H,29,31,33)",LOMMSRKZDWHERH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: 81% degradation at 100 nM;
CK1α: 70% degradation at 100 nM",G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg; human: t1/2 > 255 min; CLint < 5.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H25N3O5,471.51,471.1794,3.64,-5.57,104.81,8,2,5,5,2,3,2,0,35,8,0,0
235,CC1=C(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)N=C2C=CC=CN12,QXG-131-6,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methylimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c1-12-19(24-17-4-2-3-9-26(12)17)21(30)23-14-5-6-15-13(10-14)11-27(22(15)31)16-7-8-18(28)25-20(16)29/h2-6,9-10,16H,7-8,11H2,1H3,(H,23,30)(H,25,28,29)",HJVNRBFXIXENJT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 8.4 nM; Dmax = 84%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 92 nM; 72 h;
Cell: MOLM14; IC50 = 101 nM; 72 h; Cell: MOLM13; EC50 = 89 nM; Cell: MOLM14; EC50 = 101 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O4,417.43,417.1437,1.66,-3.81,112.88,9,2,3,5,2,3,2,2,31,9,0,0
235,CC1=C(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)N=C2C=CC=CN12,20,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methylimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c1-12-19(24-17-4-2-3-9-26(12)17)21(30)23-14-5-6-15-13(10-14)11-27(22(15)31)16-7-8-18(28)25-20(16)29/h2-6,9-10,16H,7-8,11H2,1H3,(H,23,30)(H,25,28,29)",HJVNRBFXIXENJT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 8.4 ± 2 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H19N5O4,417.43,417.1437,1.66,-3.81,112.88,9,2,3,5,2,3,2,2,31,9,0,0
300,CC1=C2N=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CN2N=C1,LC-04-113,"3-[6-(3-methylpyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17N5O3/c1-11-9-21-25-7-6-15(22-18(11)25)12-2-3-14-13(8-12)10-24(20(14)28)16-4-5-17(26)23-19(16)27/h2-3,6-9,16H,4-5,10H2,1H3,(H,23,26,27)",ZYTXPWPQWMJJJR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10 nM; Dmax = 91%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 32 nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C20H17N5O3,375.39,375.1331,1.47,-3.46,96.67,8,1,2,5,2,3,2,2,28,8,0,0
302,CC1=CC(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)=CC=C1,SJ0040,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methylbenzamide","InChI=1S/C21H19N3O4/c1-12-3-2-4-13(9-12)19(26)22-15-5-6-16-14(10-15)11-24(21(16)28)17-7-8-18(25)23-20(17)27/h2-6,9-10,17H,7-8,11H2,1H3,(H,22,26)(H,23,25,27)",HKQXTORGXDGFIQ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 20 nM; Dmax = 88.3%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,CRBN FB IC50 = 1217 nM,Assay: NanoBRET; EC50 = 100 nM;(CK1α; 2 h),,,,,https://doi.org/10.1038/s41467-024-44698-1,,,,C21H19N3O4,377.40,377.1376,2.01,-3.57,95.58,7,2,3,4,2,2,2,0,28,7,0,0
302,CC1=CC(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)=CC=C1,13,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methylbenzamide","InChI=1S/C21H19N3O4/c1-12-3-2-4-13(9-12)19(26)22-15-5-6-16-14(10-15)11-24(21(16)28)17-7-8-18(25)23-20(17)27/h2-6,9-10,17H,7-8,11H2,1H3,(H,22,26)(H,23,25,27)",HKQXTORGXDGFIQ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,10 μM,,1,non-covalent,CK1α,CK1α: DC50 = 8 nM; Dmax = 88%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 14 nM; 72 h,Assay: NanoBRET; EC50 = 100 nM;(CK1α; 2 h),,"MDCKII Papp (nm/s) AB/BA: 25/26;
m/h LM t1/2 (h)(m/h = mouse/human): 5.6/6.8; 
m/h plasma stability t1/2 (h)d(m/h = mouse/human): 5/5.7",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O4,377.40,377.1376,2.01,-3.57,95.58,7,2,3,4,2,2,2,0,28,7,0,0
319,CC1=CC=C(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)C=C1,14,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-4-methylbenzamide","InChI=1S/C21H19N3O4/c1-12-2-4-13(5-3-12)19(26)22-15-6-7-16-14(10-15)11-24(21(16)28)17-8-9-18(25)23-20(17)27/h2-7,10,17H,8-9,11H2,1H3,(H,22,26)(H,23,25,27)",XHFMAWKVKSEQSG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,2.5 μM,,1,non-covalent,CK1α,CK1α: DC50 = 7 nM; Dmax = 89%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 10 nM; 72 h,Assay: NanoBRET; EC50 = 105 nM;(CK1α; 2 h),,"MDCKII Papp (nm/s) AB/BA: 25/21;
m/h LM t1/2 (h)(μm/h = mouse/human): 4.3/7.2; 
m/h plasma stability t1/2 (h)d(μm/h = mouse/human): 10/5.7",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O4,377.40,377.1376,2.01,-3.57,95.58,7,2,3,4,2,2,2,0,28,7,0,0
320,CC1=CC=C(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,12,"N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-4-methylbenzamide","InChI=1S/C21H17N3O5/c1-11-2-4-12(5-3-11)18(26)22-13-6-7-14-15(10-13)21(29)24(20(14)28)16-8-9-17(25)23-19(16)27/h2-7,10,16H,8-9H2,1H3,(H,22,26)(H,23,25,27)",IVMUUHKIZMAKOC-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = >10000 nM; Dmax = 38%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 10000+ nM; 72 h,Assay: NanoBRET; EC50 = 202 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H17N3O5,391.38,391.1168,1.65,-3.25,112.65,8,2,3,4,2,2,2,0,29,8,0,0
321,CC1=CC=C(C(=O)NC2=CC3=C(C=C2)CN(C2CCC(=O)NC2=O)C3=O)C=C1,11,"N-[2-(2,6-dioxopiperidin-3-yl)-3-oxo-1H-isoindol-5-yl]-4-methylbenzamide","InChI=1S/C21H19N3O4/c1-12-2-4-13(5-3-12)19(26)22-15-7-6-14-11-24(21(28)16(14)10-15)17-8-9-18(25)23-20(17)27/h2-7,10,17H,8-9,11H2,1H3,(H,22,26)(H,23,25,27)",PGSLSLNXMKCQFN-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = >10000 nM; Dmax = 10%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 10000+ nM; 72 h,Assay: NanoBRET; EC50 = NA nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O4,377.40,377.1376,2.01,-3.57,95.58,7,2,3,4,2,2,2,0,28,7,0,0
322,CC1=CC=C(CNC2=CC=CC3=C2CN(C)N(C2CCC(=O)NC2=O)C3=O)C=C1,MGD-15,"3-[3-methyl-5-[(4-methylphenyl)methylamino]-1-oxo-4H-phthalazin-2-yl]piperidine-2,6-dione","InChI=1S/C22H24N4O3/c1-14-6-8-15(9-7-14)12-23-18-5-3-4-16-17(18)13-25(2)26(22(16)29)19-10-11-20(27)24-21(19)28/h3-9,19,23H,10-13H2,1-2H3,(H,24,27,28)",BUNLELBHVDUDPW-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α,293T CK1α DC50 = 0.97 µM,G-loop_beta-hairpin,,,CRBN,Q96SW2,"IC50(µM): RPMI-8226; 7.98±1.23
NCI-H929; 0.168±0.066
OPM-2; 0.103±0.052
U927; 3.81±1.45
MOLM-13; 1.34±0.89
MV-4-11; 0.508±0.142
KG-1; 0.294±0.110
Skm-1; 0.447±0.134
MUTZ-1; 2.85±0.452",,,,,,https://doi.org/10.1186/s13045-024-01592-z,,,,C22H24N4O3,392.46,392.1848,2.21,-3.79,81.75,7,2,4,4,2,2,2,0,29,7,0,0
358,CC1=CC=C(NC2=NC3=C(C4=CC=C5C(=O)N([C@H]6CCC(=O)NC6=O)CC5=C4)C=NN3C=C2)C=C1Cl,LC-02-105,"(3S)-3-[6-[5-(3-chloro-4-methylanilino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C26H21ClN6O3/c1-14-2-4-17(11-20(14)27)29-22-8-9-33-24(30-22)19(12-28-33)15-3-5-18-16(10-15)13-32(26(18)36)21-6-7-23(34)31-25(21)35/h2-5,8-12,21H,6-7,13H2,1H3,(H,29,30)(H,31,34,35)/t21-/m0/s1",FVQQKZPSORNQPE-NRFANRHFSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 68%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C26H21ClN6O3,500.95,500.1364,3.86,-6.60,108.70,9,2,4,6,2,4,2,2,36,10,0,0
368,CC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)COC2=C1,72,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methyl-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O5/c1-13-2-3-14-9-16(12-32-20(14)8-13)22(29)25-17-4-5-18-15(10-17)11-27(24(18)31)19-6-7-21(28)26-23(19)30/h2-5,8-10,19H,6-7,11-12H2,1H3,(H,25,29)(H,26,28,30)",VUGINFJQDOWAIE-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,73% degradation at 100 nM,G-loop_beta-hairpin,CK1α,64% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H21N3O5,431.45,431.1481,2.17,-3.88,104.81,8,2,3,5,3,2,3,0,32,8,0,0
381,CC1=CC=CC=C1C(=O)NC1=CC2=C(C=C1)C(=O)N(C1CCC(=O)NC1=O)C2,15,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-methylbenzamide","InChI=1S/C21H19N3O4/c1-12-4-2-3-5-15(12)19(26)22-14-6-7-16-13(10-14)11-24(21(16)28)17-8-9-18(25)23-20(17)27/h2-7,10,17H,8-9,11H2,1H3,(H,22,26)(H,23,25,27)",YDKGAFLLEDYAIB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 28 nM; Dmax = 80%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = ND nM; 72 h,Assay: NanoBRET; EC50 = 72 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O4,377.40,377.1376,2.01,-3.57,95.58,7,2,3,4,2,2,2,0,28,7,0,0
383,CC1=CC=CC2=C1CN([C@H]1CCCC(=O)NC1=O)C2=O,BXT-161,"(3S)-3-(7-methyl-3-oxo-1H-isoindol-2-yl)azepane-2,7-dione","InChI=1S/C15H16N2O3/c1-9-4-2-5-10-11(9)8-17(15(10)20)12-6-3-7-13(18)16-14(12)19/h2,4-5,12H,3,6-8H2,1H3,(H,16,18,19)/t12-/m0/s1",CNIZBMYCKRUTHY-LBPRGKRZSA-N,miscellaneous,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α;FAM83F,"CK1α: MV4-11, HCT116, DLD-1 cells
FAM83F: HCT116, DLD-1 cells",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.26508/lsa.202000804,,,,C15H16N2O3,272.30,272.1161,1.15,-2.04,66.48,5,1,1,3,2,1,2,0,20,5,0,0
384,CC1=CC=CC2=NC(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)=CN12,QXG-131-7,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-5-methylimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c1-12-3-2-4-18-24-16(11-26(12)18)20(29)23-14-5-6-15-13(9-14)10-27(22(15)31)17-7-8-19(28)25-21(17)30/h2-6,9,11,17H,7-8,10H2,1H3,(H,23,29)(H,25,28,30)",OQUSNFDKOQRACC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 3.3 nM; Dmax = 93%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 28 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; Cell: MOLM13; EC50 = 28 nM; Cell: MOLM14; EC50 = 63 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O4,417.43,417.1437,1.66,-3.81,112.88,9,2,3,5,2,3,2,2,31,9,0,0
384,CC1=CC=CC2=NC(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)=CN12,21,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-5-methylimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c1-12-3-2-4-18-24-16(11-26(12)18)20(29)23-14-5-6-15-13(9-14)10-27(22(15)31)17-7-8-19(28)25-21(17)30/h2-6,9,11,17H,7-8,10H2,1H3,(H,23,29)(H,25,28,30)",OQUSNFDKOQRACC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 3.3 ± 1.6 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H19N5O4,417.43,417.1437,1.66,-3.81,112.88,9,2,3,5,2,3,2,2,31,9,0,0
387,CC1=CC2ON=C(NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)C2C=C1,24,"3-[6-[(6-methyl-3a,7a-dihydro-1,2-benzoxazol-3-yl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C21H20N4O4/c1-11-2-4-15-17(8-11)29-24-19(15)22-13-3-5-14-12(9-13)10-25(21(14)28)16-6-7-18(26)23-20(16)27/h2-5,8-9,15-17H,6-7,10H2,1H3,(H,22,24)(H,23,26,27)",NCGUNOWSSSLNKH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,7 μM,,1,non-covalent,CK1α,CK1α: DC50 = 1 nM; Dmax = 94%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 32 nM; 72 h,,,"MDCKII Papp (nm/s) AB/BA: 30/22;
m/h LM t1/2 (h)(/h = mouse/human): 10+/ND; 
m/h plasma stability t1/2 (h)d(/h = mouse/human): 31/ND",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H20N4O4,392.42,392.1485,1.70,-2.87,100.10,8,2,2,5,4,1,3,0,29,8,0,0
419,CC1=NN2C=CC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=NC2=C1,LC-04-155,"3-[6-(2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17N5O3/c1-11-8-17-21-15(6-7-25(17)23-11)12-2-3-14-13(9-12)10-24(20(14)28)16-4-5-18(26)22-19(16)27/h2-3,6-9,16H,4-5,10H2,1H3,(H,22,26,27)",DLUKFEPFIRIULR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 90 nM; Dmax = 83%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C20H17N5O3,375.39,375.1331,1.47,-3.46,96.67,8,1,2,5,2,3,2,2,28,8,0,0
420,CC1=NN2C=CC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=NC2=C1Cl,LC-04-162,"3-[6-(3-chloro-2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H16ClN5O3/c1-10-17(21)18-22-14(6-7-26(18)24-10)11-2-3-13-12(8-11)9-25(20(13)29)15-4-5-16(27)23-19(15)28/h2-3,6-8,15H,4-5,9H2,1H3,(H,23,27,28)",KXNAVMGMZGFFGH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 12 nM; Dmax = 89%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 8 nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C20H16ClN5O3,409.83,409.0942,2.12,-4.12,96.67,8,1,2,5,2,3,2,2,29,9,0,0
453,CCCCOC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,39,"6-butoxy-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]naphthalene-2-carboxamide","InChI=1S/C28H27N3O5/c1-2-3-12-36-22-8-6-17-13-19(5-4-18(17)15-22)26(33)29-21-7-9-23-20(14-21)16-31(28(23)35)24-10-11-25(32)30-27(24)34/h4-9,13-15,24H,2-3,10-12,16H2,1H3,(H,29,33)(H,30,32,34)",LGICWZWRXNEGBB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: 81% degradation at 100 nM;
CK1α: 70% degradation at 100 nM",G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg
; human: t1/2 > 255 min; CLint < 5.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C28H27N3O5,485.54,485.1951,4.03,-5.83,104.81,8,2,7,5,2,3,2,0,36,8,0,0
500,CCOC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,37,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-ethoxynaphthalene-2-carboxamide","InChI=1S/C26H23N3O5/c1-2-34-20-7-5-15-11-17(4-3-16(15)13-20)24(31)27-19-6-8-21-18(12-19)14-29(26(21)33)22-9-10-23(30)28-25(22)32/h3-8,11-13,22H,2,9-10,14H2,1H3,(H,27,31)(H,28,30,32)",RMDIWTMEVMFWCD-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: 84% degradation at 100 nM
CK1α: 71% degradation at 100 nM",G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg; human: t1/2 > 255 min; CLint < 5.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H23N3O5,457.49,457.1638,3.25,-5.21,104.81,8,2,5,5,2,3,2,0,34,8,0,0
505,CN(C(=O)C1=CC=CC=C1)C1=CC2=C(C=C1)C(=O)N(C1CCC(=O)NC1=O)C2,10,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-N-methylbenzamide","InChI=1S/C21H19N3O4/c1-23(20(27)13-5-3-2-4-6-13)15-7-8-16-14(11-15)12-24(21(16)28)17-9-10-18(25)22-19(17)26/h2-8,11,17H,9-10,12H2,1H3,(H,22,25,26)",MYMJVTWBKDUFPG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = >10000 nM; Dmax = 12%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 10000+ nM; 72 h,Assay: NanoBRET; EC50 = NA nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O4,377.40,377.1376,1.72,-3.33,86.79,7,1,3,4,2,2,2,0,28,7,0,0
535,CN1C(=O)CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC=CC5=N4)=C3)C2=O)C1=O,QXG-6142,"N-[2-(1-methyl-2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c1-25-19(28)8-7-17(22(25)31)27-11-13-10-14(5-6-15(13)21(27)30)23-20(29)16-12-26-9-3-2-4-18(26)24-16/h2-6,9-10,12,17H,7-8,11H2,1H3,(H,23,29)",MFXWVQMUTMSWIL-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10000 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O4,417.43,417.1437,1.69,-3.79,104.09,9,1,3,5,2,3,2,2,31,9,0,0
563,CN1CC2=C(C=CC=C2NCC2=CC=C(CN3CCN(C4=CC(F)=C(C#N)C=C4)CC3)C=C2)C(=O)N1C1CCC(=O)NC1=O,MGD-28,"4-[4-[[4-[[[2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxo-4H-phthalazin-5-yl]amino]methyl]phenyl]methyl]piperazin-1-yl]-2-fluorobenzonitrile","InChI=1S/C33H34FN7O3/c1-38-21-27-26(33(44)41(38)30-11-12-31(42)37-32(30)43)3-2-4-29(27)36-19-22-5-7-23(8-6-22)20-39-13-15-40(16-14-39)25-10-9-24(18-35)28(34)17-25/h2-10,17,30,36H,11-16,19-21H2,1H3,(H,37,42,43)",JICHBFQDRLGJTM-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF1;IKZF3;CK1α,"293T; IKZF1; DC50: 3.8 nM
293T; IKZF3; DC50: 7.1 nM
293T; CK1α; DC50: 7.8 nM",G-loop_beta-hairpin,IKZF2,293T; IKZF3; DC50: 56.3 nM,CRBN,Q96SW2,"IC50(µM): RPMI-8226; 0.121±0.022
NCI-H929; 0.0041±0.0028
OPM-2; 0.0055±0.0019
U927; 0.0088±0.0075
MOLM-13; 0.0087±0.0036
MV-4-11; 0.0058±0.0019
KG-1; 0.0069±0.0032
Skm-1; 0.047±0.021
MUTZ-1; 0.017±0.0059",,"i.v: t1/2: 1.67±0.27; C0: 463.1±92.26 ng/ml; AUC(0-t): 411.7±85.56 h*µg/ml; AUC(0-int): 415.1±86.89 h*µg/ml; Vss: 10.22±2.97 L/kg; CL: 5.79±1.05 L/h/kg; MRT(0-inf): 1.75±0.28
p.o: t1/2: 3.93±0.75; Cmax: 1137±339.9 ng/ml; AUC(0-t): 2016±257.9 h*µg/ml; AUC(0-int): 2084±202.0 h*µg/ml; MRT(0-inf): 1.98±0.62; F: 82.5±10.6",,,"BALB/c nude mice bearing NCI-H929 tumor xenografts were used. NOD/SCID mice were also utilized in the study.
Oral (p.o.) administration was employed for MGD-28: In the study with BALB/c nude mice bearing NCI-H929 tumor xenografts; MGD-28 was administered at dosages of 3 mg/kg and 10 mg/kg once daily for 18 days; In the study with NOD/SCID mice; MGD-28 was administered at a dosage of 3 mg/kg once daily for 12 days.",https://doi.org/10.1186/s13045-024-01592-z,,,,C33H34FN7O3,595.68,595.2707,3.24,-6.28,112.02,10,2,7,6,3,3,3,0,44,11,0,0
581,CN1CCN(CC2=CC=C(CNC3=C4CN(C)N(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C=C2)CC1,MGD-18,"3-[3-methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]phenyl]methylamino]-1-oxo-4H-phthalazin-2-yl]piperidine-2,6-dione","InChI=1S/C27H34N6O3/c1-30-12-14-32(15-13-30)17-20-8-6-19(7-9-20)16-28-23-5-3-4-21-22(23)18-31(2)33(27(21)36)24-10-11-25(34)29-26(24)35/h3-9,24,28H,10-18H2,1-2H3,(H,29,34,35)",FLLLYDIINYIHAU-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α,293T CK1α DC50 = 0.092 µM,G-loop_beta-hairpin,,,CRBN,Q96SW2,"IC50(µM): RPMI-8226; 0.591±0.143
NCI-H929; 0.036±0.017
OPM-2; 0.049±0.016
U927; 0.072±0.36
MOLM-13; 0.146±0.043
MV-4-11; 0.017±0.059
KG-1; 0.022±0.019
Skm-1; 0.092±0.067
MUTZ-1; 0.083±0.059",,,,,,https://doi.org/10.1186/s13045-024-01592-z,,,,C27H34N6O3,490.61,490.2692,1.65,-3.66,88.23,9,2,6,5,3,2,3,0,36,9,0,0
613,COC1=C(C(=O)N2CCCC2)SC=C1C1=CN(C2CCC(=O)NC2=O)N=N1,TMX-4116,"3-[4-[4-methoxy-5-(pyrrolidine-1-carbonyl)thiophen-3-yl]triazol-1-yl]piperidine-2,6-dione","InChI=1S/C17H19N5O4S/c1-26-14-10(9-27-15(14)17(25)21-6-2-3-7-21)11-8-22(20-19-11)12-4-5-13(23)18-16(12)24/h8-9,12H,2-7H2,1H3,(H,18,23,24)",OOIINFBRWZQRRM-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α,,Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.1c01832,,,,C17H19N5O4S,389.44,389.1158,1.23,-2.63,106.42,9,1,4,4,2,2,2,2,27,10,0,0
627,COC1=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)COC2=CC=C1,74,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-5-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O6/c1-32-19-3-2-4-20-17(19)10-14(12-33-20)22(29)25-15-5-6-16-13(9-15)11-27(24(16)31)18-7-8-21(28)26-23(18)30/h2-6,9-10,18H,7-8,11-12H2,1H3,(H,25,29)(H,26,28,30)",RFENVQIDXQQDHS-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,75% degradation at 100 nM,G-loop_beta-hairpin,CK1α;IKZF1,"CK1α: 59% degradation at 100 nM
IKZF1: 39% degradation at 100 nM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H21N3O6,447.45,447.1430,1.87,-3.59,114.04,9,2,4,5,3,2,3,0,33,9,0,0
630,COC1=C2OCC(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=CC2=CC(Br)=C1,80,"6-bromo-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H20BrN3O6/c1-33-19-9-15(25)7-12-6-14(11-34-21(12)19)22(30)26-16-2-3-17-13(8-16)10-28(24(17)32)18-4-5-20(29)27-23(18)31/h2-3,6-9,18H,4-5,10-11H2,1H3,(H,26,30)(H,27,29,31)",YNOJNFLEQWRPEG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,74% degradation at 100 nM,G-loop_beta-hairpin,CK1α,65% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20BrN3O6,526.34,525.0535,2.63,-4.73,114.04,9,2,4,5,3,2,3,0,34,10,0,0
632,COC1=CC(C(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)=CC=C1OC1=CC=CC=C1,69,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methoxy-4-phenoxybenzamide","InChI=1S/C27H23N3O6/c1-35-23-14-16(7-11-22(23)36-19-5-3-2-4-6-19)25(32)28-18-8-9-20-17(13-18)15-30(27(20)34)21-10-12-24(31)29-26(21)33/h2-9,11,13-14,21H,10,12,15H2,1H3,(H,28,32)(H,29,31,33)",CUVDVAHHZNRMJJ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,55% degradation at 100 nM,G-loop_beta-hairpin,CK1α,48% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H23N3O6,485.50,485.1587,3.50,-5.37,114.04,9,2,6,5,2,3,2,0,36,9,0,0
633,COC1=CC(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)=CC=C1,19,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methoxybenzamide","InChI=1S/C21H19N3O5/c1-29-15-4-2-3-12(10-15)19(26)22-14-5-6-16-13(9-14)11-24(21(16)28)17-7-8-18(25)23-20(17)27/h2-6,9-10,17H,7-8,11H2,1H3,(H,22,26)(H,23,25,27)",MNOPHTXOYIDKKA-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,79 μM,,1,non-covalent,CK1α,CK1α: DC50 = 6 nM; Dmax = 90%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 22 nM; 72 h,Assay: NanoBRET; EC50 = 64 nM;(CK1α; 2 h),,"MDCKII Papp (nm/s) AB/BA: 17/22;
m/h LM t1/2 (h)(m/h = mouse/human): 10+/10+; 
m/h plasma stability t1/2 (h)d(m/h = mouse/human): 9.6/10",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H19N3O5,393.40,393.1325,1.71,-3.28,104.81,8,2,4,4,2,2,2,0,29,8,0,0
641,COC1=CC(OC2=CC=CC=C2)=CC=C1C(=O)NC1=CC=C2C(=O)N(C3CCC(=O)NC3=O)CC2=C1,70,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-methoxy-4-phenoxybenzamide","InChI=1S/C27H23N3O6/c1-35-23-14-19(36-18-5-3-2-4-6-18)8-10-21(23)25(32)28-17-7-9-20-16(13-17)15-30(27(20)34)22-11-12-24(31)29-26(22)33/h2-10,13-14,22H,11-12,15H2,1H3,(H,28,32)(H,29,31,33)",SSGXQMNAQRSFRQ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,82% degradation at 100 nM,G-loop_beta-hairpin,CK1α,64% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H23N3O6,485.50,485.1587,3.50,-5.37,114.04,9,2,6,5,2,3,2,0,36,9,0,0
642,COC1=CC=C(/C=C/C(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C=C1,65,"(E)-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-(4-methoxyphenyl)prop-2-enamide","InChI=1S/C23H21N3O5/c1-31-17-6-2-14(3-7-17)4-10-20(27)24-16-5-8-18-15(12-16)13-26(23(18)30)19-9-11-21(28)25-22(19)29/h2-8,10,12,19H,9,11,13H2,1H3,(H,24,27)(H,25,28,29)/b10-4+",XKHJZGRFJRADNW-ONNFQVAWSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,75% degradation at 100 nM,G-loop_beta-hairpin,CK1α,64% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C23H21N3O5,419.44,419.1481,2.11,-3.66,104.81,8,2,5,4,2,2,2,0,31,8,0,0
677,COC1=CC=C(CCC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C=C1,66,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-(4-methoxyphenyl)propanamide","InChI=1S/C23H23N3O5/c1-31-17-6-2-14(3-7-17)4-10-20(27)24-16-5-8-18-15(12-16)13-26(23(18)30)19-9-11-21(28)25-22(19)29/h2-3,5-8,12,19H,4,9-11,13H2,1H3,(H,24,27)(H,25,28,29)",LWFHNBPCMHJPOM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;IKZF1,"IKZF2: 76% degradation at 100 nM;
IKZF1: 82% degradation at 100 nM",G-loop_beta-hairpin,CK1α,40% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C23H23N3O5,421.45,421.1638,2.03,-3.57,104.81,8,2,6,4,2,2,2,0,31,8,0,0
684,COC1=CC=C(NC2=NC3=C(C4=CC=C5C(=O)N([C@H]6CCC(=O)NC6=O)CC5=C4)C=NN3C=C2)C=C1C,LC-02-121,"(3S)-3-[6-[5-(4-methoxy-3-methylanilino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C27H24N6O4/c1-15-11-18(4-7-22(15)37-2)29-23-9-10-33-25(30-23)20(13-28-33)16-3-5-19-17(12-16)14-32(27(19)36)21-6-8-24(34)31-26(21)35/h3-5,7,9-13,21H,6,8,14H2,1-2H3,(H,29,30)(H,31,34,35)/t21-/m0/s1",LIRALDJVEGMUCK-NRFANRHFSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 1%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C27H24N6O4,496.53,496.1859,3.22,-5.93,117.93,10,2,5,6,2,4,2,2,37,10,0,0
694,COC1=CC=C(OC2=CC=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=C2)C=C1,68,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-4-(4-methoxyphenoxy)benzamide","InChI=1S/C27H23N3O6/c1-35-19-7-9-21(10-8-19)36-20-5-2-16(3-6-20)25(32)28-18-4-11-22-17(14-18)15-30(27(22)34)23-12-13-24(31)29-26(23)33/h2-11,14,23H,12-13,15H2,1H3,(H,28,32)(H,29,31,33)",SSPLTBJVNWLIKS-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,54% degradation at 100 nM,G-loop_beta-hairpin,CK1α,45% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H23N3O6,485.50,485.1587,3.50,-5.37,114.04,9,2,6,5,2,3,2,0,36,9,0,0
695,COC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=C2)C=C1,67,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-(4-methoxyphenoxy)benzamide","InChI=1S/C27H23N3O6/c1-35-19-6-8-20(9-7-19)36-21-4-2-3-16(14-21)25(32)28-18-5-10-22-17(13-18)15-30(27(22)34)23-11-12-24(31)29-26(23)33/h2-10,13-14,23H,11-12,15H2,1H3,(H,28,32)(H,29,31,33)",LWWKIWAZJUFBAX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;IKZF1,"IKZF2: 90% degradation at 100 nM;
IKZF1: 99% degradation at 100 nM",G-loop_beta-hairpin,CK1α,65% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H23N3O6,485.50,485.1587,3.50,-5.37,114.04,9,2,6,5,2,3,2,0,36,9,0,0
697,COC1=CC=C2C(=C1)SC1=NC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=C(NCC3=CC=CC=C3)N12,Compound 3,"3-[6-[1-(benzylamino)-6-methoxyimidazo[2,1-b][1,3]benzothiazol-2-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C30H25N5O4S/c1-39-20-8-10-22-24(14-20)40-30-33-26(27(35(22)30)31-15-17-5-3-2-4-6-17)18-7-9-21-19(13-18)16-34(29(21)38)23-11-12-25(36)32-28(23)37/h2-10,13-14,23,31H,11-12,15-16H2,1H3,(H,32,36,37)",MBJIENHTLFHQHB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 2133 nM; CK1α DC50: 46 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,GSPT1,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 = 1700nM;
Cell: SUDHL5; EC50 = 140nM;
Cell: Molm14; EC50 = 46nM;
Cell: NB-4; EC50 = 21nM;
Cell:LoVo; EC50 = 40nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C30H25N5O4S,551.63,551.1627,4.60,-8.34,105.04,9,2,6,7,2,5,2,2,40,10,0,0
698,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,DEG-35,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxynaphthalene-2-carboxamide","InChI=1S/C25H21N3O5/c1-33-19-6-4-14-10-16(3-2-15(14)12-19)23(30)26-18-5-7-20-17(11-18)13-28(25(20)32)21-8-9-22(29)27-24(21)31/h2-7,10-12,21H,8-9,13H2,1H3,(H,26,30)(H,27,29,31)",JGWFFKIYBDZDFI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: DC50 = 1.4 nM; Dmax = 84%
CK1α: DC50 = 4.4 nM; Dmax = 92%",G-loop_beta-hairpin,IKZF1;IKZF4,"IKZF1: 55% degradation at 100 nM;
IKZF4: 33% degradation at 100 nM",CRBN,Q96SW2,"Cell: MOLM-13; IC50 = 0.0057 μM
Cell: OCI-AML5; IC50 = 0.011 μM
Cell: MOLM-14; IC50 = 0.015 μM
Cell: KG1A; IC50 = 0.3930 μM
Cell: KASUMI-1; IC50 = 1.006 μM
Cell: NOMO-1; IC50 = 14.3570 μM
Cell: OCI-AML3; IC50 = 18.1630 μM
Cell: NB-4; IC50 = 27.86 μM
Cell: BM; IC50 = 15.7 nM
Cell: AML PDX1; IC50 = 2.8 nM
Cell: AML PDX2; IC50 = 5.2 nM",,"Administration route: intraperitoneal injection
Dose: 50 mg/kg
t1/2 = 2.54 h
Tmax = 0.67 h
Cmax = 0.5 ng/mL
AUClast = 12512 h*ng/mL
AUCINF_obs = 2.45 h*ng/mL",,,"MLL-AF9 CrbnI391V mouse model
Administration route: intraperitoneal injection
Dose: 50 mg/kg
Result: Significant prolonged survival",https://doi.org/10.1016/j.ccell.2023.02.010,,,,C25H21N3O5,443.46,443.1481,2.86,-4.90,104.81,8,2,4,5,2,3,2,0,33,8,0,0
698,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,DEG-35,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxynaphthalene-2-carboxamide","InChI=1S/C25H21N3O5/c1-33-19-6-4-14-10-16(3-2-15(14)12-19)23(30)26-18-5-7-20-17(11-18)13-28(25(20)32)21-8-9-22(29)27-24(21)31/h2-7,10-12,21H,8-9,13H2,1H3,(H,26,30)(H,27,29,31)",JGWFFKIYBDZDFI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,IKZF2: 90% degradation at 100 nM; 94% degradation at 1 μM;CK1α: 70% degradation at 100 nM 70% degradation at 1 μM,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell:A2780;EC50 =  12 nM
Cell:OCI-LY3;EC50 = 8 nM
Cell:NCI-H1048;EC50 = 49 nM",,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 = 188 min; CLint = 7.4 μL/min/mg; human: t1/2 = 3.8 min; CLint = 361.9 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C25H21N3O5,443.46,443.1481,2.86,-4.90,104.81,8,2,4,5,2,3,2,0,33,8,0,0
699,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=N1,44,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-methoxyquinoline-6-carboxamide","InChI=1S/C24H20N4O5/c1-33-21-9-3-13-10-14(2-6-18(13)26-21)22(30)25-16-4-5-17-15(11-16)12-28(24(17)32)19-7-8-20(29)27-23(19)31/h2-6,9-11,19H,7-8,12H2,1H3,(H,25,30)(H,27,29,31)",XTFMZGLRKNVGSN-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,89% degradation at 100 nM,G-loop_beta-hairpin,CK1α,68% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg; human: t1/2 =16.1 min; CLint =108.3 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
700,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=NC2=C1,43,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methoxyquinoline-3-carboxamide","InChI=1S/C24H20N4O5/c1-33-17-4-2-13-8-14(11-25-19(13)10-17)22(30)26-16-3-5-18-15(9-16)12-28(24(18)32)20-6-7-21(29)27-23(20)31/h2-5,8-11,20H,6-7,12H2,1H3,(H,26,30)(H,27,29,31)",ZNHJWWINKUGUKI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,73% degradation at 100 nM,G-loop_beta-hairpin,CK1α,62% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg; human: t1/2 =20.3 min; CLint =68.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
701,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)COC2=C1,76,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O6/c1-32-17-4-2-13-8-15(12-33-20(13)10-17)22(29)25-16-3-5-18-14(9-16)11-27(24(18)31)19-6-7-21(28)26-23(19)30/h2-5,8-10,19H,6-7,11-12H2,1H3,(H,25,29)(H,26,28,30)",HGLQKZHORDECOX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,60% degradation at 100 nM,G-loop_beta-hairpin,IKZF2,57% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H21N3O6,447.45,447.1430,1.87,-3.59,114.04,9,2,4,5,3,2,3,0,33,9,0,0
702,COC1=CC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=CC2=C1,42,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methoxyisoquinoline-3-carboxamide","InChI=1S/C24H20N4O5/c1-33-17-4-2-13-10-19(25-11-14(13)9-17)22(30)26-16-3-5-18-15(8-16)12-28(24(18)32)20-6-7-21(29)27-23(20)31/h2-5,8-11,20H,6-7,12H2,1H3,(H,26,30)(H,27,29,31)",FBESMAXFWMZKLU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,68% degradation at 100 nM,G-loop_beta-hairpin,CK1α,61% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 =209 min; CLint =6.6 μL/min/mg; human: t1/2 =15.9 min; CLint =87.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
706,COC1=CC=C2N=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,41,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxyquinoline-2-carboxamide","InChI=1S/C24H20N4O5/c1-33-16-4-7-18-13(11-16)2-6-19(26-18)22(30)25-15-3-5-17-14(10-15)12-28(24(17)32)20-8-9-21(29)27-23(20)31/h2-7,10-11,20H,8-9,12H2,1H3,(H,25,30)(H,27,29,31)",KGOVKOKKVYFUAP-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,87% degradation at 100 nM,G-loop_beta-hairpin,CK1α,69% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 =23.9 min; CLint =57.9 μL/min/mg; human: t1/2 =15.9 min; CLint =87.4 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
707,COC1=CC=C2OCC(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=CC2=C1,75,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O6/c1-32-17-3-6-20-13(10-17)8-15(12-33-20)22(29)25-16-2-4-18-14(9-16)11-27(24(18)31)19-5-7-21(28)26-23(19)30/h2-4,6,8-10,19H,5,7,11-12H2,1H3,(H,25,29)(H,26,28,30)",AOZLNZRSVIVLQX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,75% degradation at 100 nM,G-loop_beta-hairpin,CK1α,66% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H21N3O6,447.45,447.1430,1.87,-3.59,114.04,9,2,4,5,3,2,3,0,33,9,0,0
718,COC1=CC=CC2=C1OCC(C(=O)NC1=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C1)=C2,DEG-77,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O6/c1-32-19-4-2-3-13-9-15(12-33-21(13)19)22(29)25-16-5-6-17-14(10-16)11-27(24(17)31)18-7-8-20(28)26-23(18)30/h2-6,9-10,18H,7-8,11-12H2,1H3,(H,25,29)(H,26,28,30)",ZFAKJMUJUNDGEI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,82% degradation at 100 nM,G-loop_beta-hairpin,CK1α,69% degradation at 100 nM,CRBN,Q96SW2,"Cell:A2780;EC50 =  27 nM
Cell:OCI-LY3;EC50 = 14 nM",,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H21N3O6,447.45,447.1430,1.87,-3.59,114.04,9,2,4,5,3,2,3,0,33,9,0,0
718,COC1=CC=CC2=C1OCC(C(=O)NC1=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C1)=C2,DEG-77,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-methoxy-2H-chromene-3-carboxamide","InChI=1S/C24H21N3O6/c1-32-19-4-2-3-13-9-15(12-33-21(13)19)22(29)25-16-5-6-17-14(10-16)11-27(24(17)31)18-7-8-20(28)26-23(18)30/h2-6,9-10,18H,7-8,11-12H2,1H3,(H,25,29)(H,26,28,30)",ZFAKJMUJUNDGEI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,Assay:HTRF; KD = 210 nM,1,non-covalent,IKZF2;CK1α,"IKZF2: DC50 = 15.3 nM;
CK1α: DC50 = 10 nM",G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM-13; IC50 = 4 nM,,"Administration route: intraperitoneal injection
Dose: 233 mg/kg
t1/2 = 16.91 h
Tmax = 0.25 h
Cmax = 1444.63 ng/mL
AUClast = 32389.34 h*ng/mL
AUCINF_obs = 34095.74 h*ng/mL",,,"MLL-AF9 CrbnI391V mouse model.
Administration route: intraperitoneal injection
Dose: 233 mg/kg weekly
Result: significant prolonged survival",https://doi.org/10.1016/j.ccell.2023.02.010,,,,C24H21N3O6,447.45,447.1430,1.87,-3.59,114.04,9,2,4,5,3,2,3,0,33,9,0,0
720,COC1=CC=CN2C=C(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)N=C12,QXG-131-3,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-17-3-2-8-26-11-15(24-19(17)26)20(29)23-13-4-5-14-12(9-13)10-27(22(14)31)16-6-7-18(28)25-21(16)30/h2-5,8-9,11,16H,6-7,10H2,1H3,(H,23,29)(H,25,28,30)",KGLGAVMTVVETFT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 81 nM; Dmax = 93%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 42 nM; 72 h;
Cell: MOLM14; IC50 = 132 nM; 72 h; Cell: MOLM13; EC50 = 40 nM; Cell: MOLM14; EC50 = 131 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
720,COC1=CC=CN2C=C(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)N=C12,27,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-17-3-2-8-26-11-15(24-19(17)26)20(29)23-13-4-5-14-12(9-13)10-27(22(14)31)16-6-7-18(28)25-21(16)30/h2-5,8-9,11,16H,6-7,10H2,1H3,(H,23,29)(H,25,28,30)",KGLGAVMTVVETFT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 8.1 ± 2.1 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
721,COC1=CC2=C(C=C1)C(CC(=O)NC1=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C1)=CC=C2,62,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-(6-methoxynaphthalen-1-yl)acetamide","InChI=1S/C26H23N3O5/c1-34-19-6-8-20-15(12-19)3-2-4-16(20)13-24(31)27-18-5-7-21-17(11-18)14-29(26(21)33)22-9-10-23(30)28-25(22)32/h2-8,11-12,22H,9-10,13-14H2,1H3,(H,27,31)(H,28,30,32)",QJBNEXUSTCCRIM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;IKZF1,"IKZF2: 93% degradation at 100 nM
IKZF1: 98% degradation at 100 nM",G-loop_beta-hairpin,CK1α,63% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H23N3O5,457.49,457.1638,2.79,-4.88,104.81,8,2,5,5,2,3,2,0,34,8,0,0
737,COC1=CC2=C(C=CC=C2CC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C=C1,63,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-(7-methoxynaphthalen-1-yl)acetamide","InChI=1S/C26H23N3O5/c1-34-19-7-5-15-3-2-4-16(21(15)13-19)12-24(31)27-18-6-8-20-17(11-18)14-29(26(20)33)22-9-10-23(30)28-25(22)32/h2-8,11,13,22H,9-10,12,14H2,1H3,(H,27,31)(H,28,30,32)",GXJUZUWLUQFMSB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;IKZF1,"IKZF2: 92% degradation at 100 nM;
IKZF1: 97% degradation at 100 nM",G-loop_beta-hairpin,CK1α,60% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H23N3O5,457.49,457.1638,2.79,-4.88,104.81,8,2,5,5,2,3,2,0,34,8,0,0
741,COC1=CC2=NC(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)=CN2C=C1,QXG-131-1,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-14-6-7-26-11-16(24-18(26)9-14)20(29)23-13-2-3-15-12(8-13)10-27(22(15)31)17-4-5-19(28)25-21(17)30/h2-3,6-9,11,17H,4-5,10H2,1H3,(H,23,29)(H,25,28,30)",RNEWLPVIZSSIKR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 3.1 nM; Dmax = 94%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 30 nM; 72 h;
Cell: MOLM14; IC50 = 67 nM; 72 h; Cell: MOLM13; EC50 = 31 nM; Cell: MOLM14; EC50 = 67 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
741,COC1=CC2=NC(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)=CN2C=C1,25,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-14-6-7-26-11-16(24-18(26)9-14)20(29)23-13-2-3-15-12(8-13)10-27(22(15)31)17-4-5-19(28)25-21(17)30/h2-3,6-9,11,17H,4-5,10H2,1H3,(H,23,29)(H,25,28,30)",RNEWLPVIZSSIKR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 3.1 ± 1.3 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
745,COC1=CN=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,46,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methoxyquinoline-7-carboxamide","InChI=1S/C24H20N4O5/c1-33-17-9-13-2-3-14(10-19(13)25-11-17)22(30)26-16-4-5-18-15(8-16)12-28(24(18)32)20-6-7-21(29)27-23(20)31/h2-5,8-11,20H,6-7,12H2,1H3,(H,26,30)(H,27,29,31)",DPCNQUQEWFWFHL-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,64% degradation at 100 nM,G-loop_beta-hairpin,IKZF2,62% degradation at 100 nM,CRBN,Q96SW2,,,,"Liver Microsome Metabolic Stability Assay:
mouse: t1/2 > 255 min; CLint < 5.4 μL/min/mg; human: t1/2 = 24.5 min; CLint = 56.6 μL/min/mg",,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
746,COC1=CN2C=C(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)N=C2C=C1,QXG-131-2,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-14-3-6-18-24-16(11-26(18)10-14)20(29)23-13-2-4-15-12(8-13)9-27(22(15)31)17-5-7-19(28)25-21(17)30/h2-4,6,8,10-11,17H,5,7,9H2,1H3,(H,23,29)(H,25,28,30)",HRVOVFAJNZWSIH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 1.1 nM; Dmax = 96%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 14 nM; 72 h;
Cell: MOLM14; IC50 = 24 nM; 72 h; Cell: MOLM13; EC50 = 21 nM; Cell: MOLM14; EC50 = 24 nM ",,,"T1/2 in mimutes;
Human: 33.2;
Mouse: 120+","T1/2 in mimutes;
Human: 21;
Mouse: 6-",,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
746,COC1=CN2C=C(C(=O)NC3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)N=C2C=C1,22,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-methoxyimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O5/c1-32-14-3-6-18-24-16(11-26(18)10-14)20(29)23-13-2-4-15-12(8-13)9-27(22(15)31)17-5-7-19(28)25-21(17)30/h2-4,6,8,10-11,17H,5,7,9H2,1H3,(H,23,29)(H,25,28,30)",HRVOVFAJNZWSIH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 1.1 ± 1.2 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MOLM-13: IC50 = 14 nM,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H19N5O5,433.42,433.1386,1.36,-3.52,122.11,10,2,4,5,2,3,2,2,32,10,0,0
747,COC1=CSC=C1C1=CN(C2CCC(=O)NC2=O)N=N1,FPFT-2216,"3-[4-(4-methoxythiophen-3-yl)triazol-1-yl]piperidine-2,6-dione","InChI=1S/C12H12N4O3S/c1-19-10-6-20-5-7(10)8-4-16(15-14-8)9-2-3-11(17)13-12(9)18/h4-6,9H,2-3H2,1H3,(H,13,17,18)",SKUSCUALKIOIST-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1,CK1α DC50 <0.01 μM; IKZF1 DC50 <0.01 μM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MM.1S IC50 = 17 nM; NCI-H929 IC50 = 50 nM,," orally to male mice: 1.0 (mg/kg), t1/2 = 1.2 hr; AUC0-∞ = 243 (ng･hr/mL); Cmax = 135 (ng/mL); Tmax = 0.5 hr; F = 46%.
 orally to male monkeys: 0.0125 (mg/kg),  AUC0-∞ = 37 (ng･hr/mL).
 orally to male monkeys: 0.025 (mg/kg),  AUC0-∞ = 62 (ng･hr/mL).
",,," NOD SCID mice subcutaneously transplanted with NCI-H929 cells.
 orally once daily for 5 consecutive days per week for 4 weeks.
 1 mg/kg, T/C = -1.6 %; 0.1 mg/kg, T/C = 43.4 %; 0.01 mg/kg, T/C = 70.2 %",https://doi.org/10.1016/j.bmcl.2025.130193,,,,C12H12N4O3S,292.32,292.0630,0.99,-2.20,86.11,7,1,3,3,1,2,1,2,20,8,0,0
750,COC1=NC=C2C=C(C(=O)NC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CC2=C1,45,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-methoxyisoquinoline-7-carboxamide","InChI=1S/C24H20N4O5/c1-33-21-10-13-2-3-14(8-15(13)11-25-21)22(30)26-17-4-5-18-16(9-17)12-28(24(18)32)19-6-7-20(29)27-23(19)31/h2-5,8-11,19H,6-7,12H2,1H3,(H,26,30)(H,27,29,31)",BWEJJXAXDRVATO-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: 88% degradation at 100 nM
CK1α: 72% degradation at 100 nM",G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H20N4O5,444.45,444.1434,2.26,-4.34,117.70,9,2,4,5,2,3,2,1,33,9,0,0
757,CSC1=CSC=C1C1=CN(C2CCC(=O)NC2=O)N=N1,TMX-4113,"3-[4-(4-methylsulfanylthiophen-3-yl)triazol-1-yl]piperidine-2,6-dione","InChI=1S/C12H12N4O2S2/c1-19-10-6-20-5-7(10)8-4-16(15-14-8)9-2-3-11(17)13-12(9)18/h4-6,9H,2-3H2,1H3,(H,13,17,18)",YIIUEHDPOPLUBR-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,CK1α,,Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.1c01832,,,,C12H12N4O2S2,308.39,308.0402,1.71,-2.93,76.88,6,1,3,3,1,2,1,2,20,8,0,0
760,N#CC1=C2N=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CN2N=C1,LC-04-077,"5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carbonitrile","InChI=1S/C20H14N6O3/c21-8-13-9-22-26-6-5-15(23-18(13)26)11-1-2-14-12(7-11)10-25(20(14)29)16-3-4-17(27)24-19(16)28/h1-2,5-7,9,16H,3-4,10H2,(H,24,27,28)",NMJBTMAEPJCFSH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 406 nM; Dmax = 93%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C20H14N6O3,386.37,386.1127,1.03,-3.05,120.46,9,1,2,5,2,3,2,2,29,9,0,0
761,N#CC1=CC(C(=O)NC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3)=CC=C1,18,"3-cyano-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]benzamide","InChI=1S/C21H16N4O4/c22-10-12-2-1-3-13(8-12)19(27)23-15-4-5-16-14(9-15)11-25(21(16)29)17-6-7-18(26)24-20(17)28/h1-5,8-9,17H,6-7,11H2,(H,23,27)(H,24,26,28)",LRPSTRPEQAKYBN-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 15 nM; Dmax = 88%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 84 nM; 72 h,Assay: NanoBRET; EC50 = 489 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H16N4O4,388.38,388.1172,1.57,-3.16,119.37,8,2,3,4,2,2,2,0,29,8,0,0
778,NC1=C(C2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)N=C2C=CC=CN12,Compound 8,"3-[6-(3-aminoimidazo[1,2-a]pyridin-2-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17N5O3/c21-18-17(22-15-3-1-2-8-24(15)18)11-4-5-13-12(9-11)10-25(20(13)28)14-6-7-16(26)23-19(14)27/h1-5,8-9,14H,6-7,10,21H2,(H,23,26,27)",DSESRVIUYQBZFJ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 18 nM; CK1α DC50: 26 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 = 2300nM;
Cell: SUDHL5; EC50 = 104nM;
Cell: Molm14; EC50 = 730nM;
Cell: NB-4; EC50 = 1300nM;
Cell: LoVo; EC50 = 600nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C20H17N5O3,375.39,375.1331,1.34,-3.10,109.80,8,3,2,5,2,3,2,2,28,8,0,0
784,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC(C(F)(F)F)=C1,F3C-Le,"3-[7-amino-3-oxo-5-(trifluoromethyl)-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C14H12F3N3O3/c15-14(16,17)6-3-7-8(9(18)4-6)5-20(13(7)23)10-1-2-11(21)19-12(10)22/h3-4,10H,1-2,5,18H2,(H,19,21,22)",NSKZOWZDLMSORX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1,"Assay: HiBit
 CK1α: DC50 = (N/A) Dmax = 94.57% IKZF1: DC50 = (N/A) Dmax = 87.72%",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1038/s41467-023-40385-9,,,,C14H12F3N3O3,327.26,327.0831,1.05,-1.90,92.50,6,3,1,3,2,1,2,0,23,9,0,0
785,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC(OC(F)(F)F)=C1,F3CO-Le,"3-[7-amino-3-oxo-5-(trifluoromethoxy)-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C14H12F3N3O4/c15-14(16,17)24-6-3-7-8(9(18)4-6)5-20(13(7)23)10-1-2-11(21)19-12(10)22/h3-4,10H,1-2,5,18H2,(H,19,21,22)",CFLQOYFUGDVTBH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1;SALL4,"Assay: HiBit
IKZF1: DC50 = (N/A) Dmax = 108.6% CK1α: DC50 = 945 nM Dmax = 76.63%  SALL4: DC50 = (N/A) Dmax = 93.23%",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1038/s41467-023-40385-9,,,,C14H12F3N3O4,343.26,343.0780,0.93,-1.73,101.73,7,3,2,3,2,1,2,0,24,10,0,0
787,NC1=C2N=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)C=CN2N=C1,LC-04-081,"3-[6-(3-aminopyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C19H16N6O3/c20-13-8-21-25-6-5-14(22-17(13)25)10-1-2-12-11(7-10)9-24(19(12)28)15-3-4-16(26)23-18(15)27/h1-2,5-8,15H,3-4,9,20H2,(H,23,26,27)",APQSXHQOFJECJP-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >1000 nM; Dmax = 31%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C19H16N6O3,376.38,376.1284,0.74,-2.55,122.69,9,3,2,5,2,3,2,2,28,9,0,0
789,NC1=CC(Br)=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Br-Le,"3-(7-amino-5-bromo-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C13H12BrN3O3/c14-6-3-7-8(9(15)4-6)5-17(13(7)20)10-1-2-11(18)16-12(10)19/h3-4,10H,1-2,5,15H2,(H,16,18,19)",IIAHEYPYLVKWSS-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1,"Assay: HiBit
IKZF1: DC50 = (N/A) Dmax = 97.72% CK1α: DC50 = (N/A)Dmax = 83.51%",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1038/s41467-023-40385-9,,,,C13H12BrN3O3,338.16,337.0062,0.79,-1.78,92.50,6,3,1,3,2,1,2,0,20,7,0,0
791,NC1=CC(Cl)=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Cl-Le,"3-(7-amino-5-chloro-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C13H12ClN3O3/c14-6-3-7-8(9(15)4-6)5-17(13(7)20)10-1-2-11(18)16-12(10)19/h3-4,10H,1-2,5,15H2,(H,16,18,19)",UKKIIMSPHWNLNC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1,"Assay: HiBit
 IKZF1: DC50 = 190.5 nM Dmax = 71.96% CK1α: DC50 = 230.1 nM Dmax = 71.38%",Unknown,,,CRBN,Q96SW2,"Cell: MM1.S GI50=144.3nm GImax=38.45
Cell: H929 GI50=913.3nm GImax=36.49
Cell: MDS-L GI50=62.33 nm GImax=75.08",,,,,,https://doi.org/10.1038/s41467-023-40385-9,,,,C13H12ClN3O3,293.71,293.0567,0.68,-1.44,92.50,6,3,1,3,2,1,2,0,20,7,0,0
794,NC1=CC(F)=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,F-Le,"3-(7-amino-5-fluoro-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C13H12FN3O3/c14-6-3-7-8(9(15)4-6)5-17(13(7)20)10-1-2-11(18)16-12(10)19/h3-4,10H,1-2,5,15H2,(H,16,18,19)",ZLSXUIDRXBLOLG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;IKZF1,"Assay: HiBit
 CK1α: DC50 = 121.5 nM Dmax = 47.35% IKZF1: DC50 = 21.54 nM Dmax = 41.54%",Unknown,,,CRBN,Q96SW2,"Cell: MM1.S GI50=26.05nm GImax=14.92
Cell: H929 GI50=84.27nm GImax=7.61
Cell: MDS-L GI50=11.16 nm GImax=45.88",,,,,,https://doi.org/10.1038/s41467-023-40385-9,,,,C13H12FN3O3,277.25,277.0863,0.17,-0.98,92.50,6,3,1,3,2,1,2,0,20,7,0,0
825,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Pomalidomide,"4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione","InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Approval,,,,,,,,1,non-covalent,IKZF1,Cell: MV4-11,Unknown,CK1α;FAM83F,"CK1α: MV4-11 cell; FAM83F: HCT116, DLD-1; HaCaT cells.",CRBN,Q96SW2,,,,,,,https://doi.org/10.26508/lsa.202000804,,,,C13H11N3O4,273.25,273.0750,-0.33,-0.45,109.57,7,3,1,3,2,1,2,0,20,7,0,0
825,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,3(poma),"4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione","InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Approval,,,,,,,Assay: FP; IC50 = 0.64 ± 0.39 μM; Assay: TEA; IC50 = 0.02 ± 0.01 μM,1,non-covalent,SALL4;IKZF2;GSPT1;CK1α;IKZF3,,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1002/cbic.202300351,8OIZ,8OIZ:Y70,,C13H11N3O4,273.25,273.0750,-0.33,-0.45,109.57,7,3,1,3,2,1,2,0,20,7,0,0
828,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Lenalidomide,"3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Approval,,,,,,,,1,non-covalent,CK1α,,G-loop_beta-hairpin,IKZF1;IKZF3,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1038/nature14610,,,,C13H13N3O3,259.26,259.0957,0.03,-0.77,92.50,6,3,1,3,2,1,2,0,19,6,0,0
828,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Lenalidomide,"3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Approval,,,,,,,,1,non-covalent,IKZF1,Cell: MV4-11,G-loop_beta-hairpin,CK1α;FAM83F,"CK1α: MV4-11 cell; FAM83F: HCT116, DLD-1; HaCaT cells.",CRBN,Q96SW2,,,,,,,https://doi.org/10.26508/lsa.202000804,,,,C13H13N3O3,259.26,259.0957,0.03,-0.77,92.50,6,3,1,3,2,1,2,0,19,6,0,0
850,O=C(/C=C/C1=CC=CC=C1)NC1=CC=C2C(=O)N(C3CCC(=O)NC3=O)CC2=C1,50,"(E)-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-phenylprop-2-enamide","InChI=1S/C22H19N3O4/c26-19(10-6-14-4-2-1-3-5-14)23-16-7-8-17-15(12-16)13-25(22(17)29)18-9-11-20(27)24-21(18)28/h1-8,10,12,18H,9,11,13H2,(H,23,26)(H,24,27,28)/b10-6+",VWGBLNAJOOBMEC-UXBLZVDNSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,71% degradation at 100 nM,G-loop_beta-hairpin,CK1α,60% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C22H19N3O4,389.41,389.1376,2.10,-3.66,95.58,7,2,4,4,2,2,2,0,29,7,0,0
917,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(Cl)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-047-P2,"(3S)-3-[6-(5-chloropyrazolo[1,5-a]pyrimidin-3-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C19H14ClN5O3/c20-15-5-6-25-17(22-15)13(8-21-25)10-1-2-12-11(7-10)9-24(19(12)28)14-3-4-16(26)23-18(14)27/h1-2,5-8,14H,3-4,9H2,(H,23,26,27)/t14-/m0/s1",DMUSJBLCTPEHPQ-AWEZNQCLSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 50%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C19H14ClN5O3,395.81,395.0785,1.81,-3.82,96.67,8,1,2,5,2,3,2,2,28,9,0,0
918,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NC6=CC=C7OCOC7=C6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-104,"(3S)-3-[6-[5-(1,3-benzodioxol-5-ylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C26H20N6O5/c33-23-6-4-19(25(34)30-23)31-12-15-9-14(1-3-17(15)26(31)35)18-11-27-32-8-7-22(29-24(18)32)28-16-2-5-20-21(10-16)37-13-36-20/h1-3,5,7-11,19H,4,6,12-13H2,(H,28,29)(H,30,33,34)/t19-/m0/s1",BIRKQAVFJFRNPQ-IBGZPJMESA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C26H20N6O5,496.48,496.1495,2.63,-5.45,127.16,11,2,4,7,3,4,3,2,37,11,0,0
919,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NC6CCC(F)(F)CC6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-135,"(3S)-3-[6-[5-[(4,4-difluorocyclohexyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H24F2N6O3/c26-25(27)8-5-16(6-9-25)29-20-7-10-33-22(30-20)18(12-28-33)14-1-2-17-15(11-14)13-32(24(17)36)19-3-4-21(34)31-23(19)35/h1-2,7,10-12,16,19H,3-6,8-9,13H2,(H,29,30)(H,31,34,35)/t19-/m0/s1",KOYRQYHKBOGVHK-IBGZPJMESA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C25H24F2N6O3,494.50,494.1878,3.15,-5.29,108.70,9,2,4,6,3,3,2,2,36,11,0,0
920,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NC6CCCCC6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-119,"(3S)-3-[6-[5-(cyclohexylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H26N6O3/c32-22-9-8-20(24(33)29-22)30-14-16-12-15(6-7-18(16)25(30)34)19-13-26-31-11-10-21(28-23(19)31)27-17-4-2-1-3-5-17/h6-7,10-13,17,20H,1-5,8-9,14H2,(H,27,28)(H,29,32,33)/t20-/m0/s1",UYDLBNIXPOLYLS-FQEVSTJZSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 9%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C25H26N6O3,458.52,458.2066,2.90,-4.90,108.70,9,2,4,6,3,3,2,2,34,9,0,0
921,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NC6CCOCC6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-120,"(3S)-3-[6-[5-(oxan-4-ylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C24H24N6O4/c31-21-4-3-19(23(32)28-21)29-13-15-11-14(1-2-17(15)24(29)33)18-12-25-30-8-5-20(27-22(18)30)26-16-6-9-34-10-7-16/h1-2,5,8,11-12,16,19H,3-4,6-7,9-10,13H2,(H,26,27)(H,28,31,32)/t19-/m0/s1",GCUFXMIQFJJOPR-IBGZPJMESA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 14%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C24H24N6O4,460.49,460.1859,1.75,-3.97,117.93,10,2,4,6,3,3,3,2,34,10,0,0
922,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NCC6=CC=CC=C6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-116,"(3S)-3-[6-[5-(benzylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C26H22N6O3/c33-23-9-8-21(25(34)30-23)31-15-18-12-17(6-7-19(18)26(31)35)20-14-28-32-11-10-22(29-24(20)32)27-13-16-4-2-1-3-5-16/h1-7,10-12,14,21H,8-9,13,15H2,(H,27,29)(H,30,33,34)/t21-/m0/s1",YGLDMGSRTJAXRL-NRFANRHFSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 30%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C26H22N6O3,466.50,466.1753,2.77,-5.56,108.70,9,2,5,6,2,4,2,2,35,9,0,0
923,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NCCC6=CC=CC=C6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-117,"(3S)-3-[3-oxo-6-[5-(2-phenylethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C27H24N6O3/c34-24-9-8-22(26(35)31-24)32-16-19-14-18(6-7-20(19)27(32)36)21-15-29-33-13-11-23(30-25(21)33)28-12-10-17-4-2-1-3-5-17/h1-7,11,13-15,22H,8-10,12,16H2,(H,28,30)(H,31,34,35)/t22-/m0/s1",IWELENJZEKXIMC-QFIPXVFZSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C27H24N6O3,480.53,480.1910,2.81,-5.62,108.70,9,2,6,6,2,4,2,2,36,9,0,0
924,O=C1CC[C@H](N2CC3=CC(C4=C5N=C(NCCN6CCOCC6)C=CN5N=C4)=CC=C3C2=O)C(=O)N1,LC-02-148,"(3S)-3-[6-[5-(2-morpholin-4-ylethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H27N7O4/c33-22-4-3-20(24(34)29-22)31-15-17-13-16(1-2-18(17)25(31)35)19-14-27-32-7-5-21(28-23(19)32)26-6-8-30-9-11-36-12-10-30/h1-2,5,7,13-14,20H,3-4,6,8-12,15H2,(H,26,28)(H,29,33,34)/t20-/m0/s1",XMQLJWPGJYURGC-FQEVSTJZSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = >100 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C25H27N7O4,489.54,489.2125,0.90,-3.33,121.17,11,2,6,6,3,3,3,2,36,11,0,0
957,O=C1CCC(N2C(=O)C3=C(C=C(NC(=O)C4=CC5=CC=CC=C5N=C4)C=C3)C2=O)C(=O)N1,QXG-6477,"N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]quinoline-3-carboxamide","InChI=1S/C23H16N4O5/c28-19-8-7-18(21(30)26-19)27-22(31)15-6-5-14(10-16(15)23(27)32)25-20(29)13-9-12-3-1-2-4-17(12)24-11-13/h1-6,9-11,18H,7-8H2,(H,25,29)(H,26,28,30)",FPVLNQQAQVKLMH-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 79 nM; Dmax = 55%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C23H16N4O5,428.40,428.1121,1.89,-4.02,125.54,9,2,3,5,2,3,2,1,32,9,0,0
957,O=C1CCC(N2C(=O)C3=C(C=C(NC(=O)C4=CC5=CC=CC=C5N=C4)C=C3)C2=O)C(=O)N1,8,"N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]quinoline-3-carboxamide","InChI=1S/C23H16N4O5/c28-19-8-7-18(21(30)26-19)27-22(31)15-6-5-14(10-16(15)23(27)32)25-20(29)13-9-12-3-1-2-4-17(12)24-11-13/h1-6,9-11,18H,7-8H2,(H,25,29)(H,26,28,30)",FPVLNQQAQVKLMH-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 79 ± 6 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C23H16N4O5,428.40,428.1121,1.89,-4.02,125.54,9,2,3,5,2,3,2,1,32,9,0,0
959,O=C1CCC(N2C(=O)C3=C(C=C(NC(=O)C4=CN5C=CC=CC5=N4)C=C3)C2=O)C(=O)N1,QXG-6471,"N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H15N5O5/c27-17-7-6-15(19(29)24-17)26-20(30)12-5-4-11(9-13(12)21(26)31)22-18(28)14-10-25-8-2-1-3-16(25)23-14/h1-5,8-10,15H,6-7H2,(H,22,28)(H,24,27,29)",PEGYPANAEKMMQM-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 88 nM; Dmax = 63%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H15N5O5,417.38,417.1073,0.99,-3.21,129.95,10,2,3,5,2,3,2,2,31,10,0,0
959,O=C1CCC(N2C(=O)C3=C(C=C(NC(=O)C4=CN5C=CC=CC5=N4)C=C3)C2=O)C(=O)N1,7,"N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H15N5O5/c27-17-7-6-15(19(29)24-17)26-20(30)12-5-4-11(9-13(12)21(26)31)22-18(28)14-10-25-8-2-1-3-16(25)23-14/h1-5,8-10,15H,6-7H2,(H,22,28)(H,24,27,29)",PEGYPANAEKMMQM-UHFFFAOYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 88 ± 22 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H15N5O5,417.38,417.1073,0.99,-3.21,129.95,10,2,3,5,2,3,2,2,31,10,0,0
972,O=C1CCC(N2C(=O)C3=C(C2=O)C(C2=C[C@@]2(COOCC(Cl)(Cl)Cl)C2=CC=C(Br)C=C2)=CC=C3)C(=O)N1,20b,"4-[(3S)-3-(4-bromophenyl)-3-(2,2,2-trichloroethylperoxymethyl)cyclopropen-1-yl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione","InChI=1S/C25H18BrCl3N2O6/c26-14-6-4-13(5-7-14)24(11-36-37-12-25(27,28)29)10-17(24)15-2-1-3-16-20(15)23(35)31(22(16)34)18-8-9-19(32)30-21(18)33/h1-7,10,18H,8-9,11-12H2,(H,30,32,33)/t18?,24-/m1/s1",PEXVJXROJKUUCZ-VCUSLETLSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;CK1α;GSPT1;SALL4,"IKZF3: EC50 = 3.7 μM
CK1α: EC50 = 2.1 μM
GSPT1: EC50 = 5.1 μM
SALL4: EC50 = 2.8 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H18BrCl3N2O6,628.69,625.9414,4.50,-6.99,102.01,8,1,7,5,3,2,2,0,37,12,0,0
973,O=C1CCC(N2C(=O)C3=C(C2=O)C(C2=C[C@]2(C(=O)OCC(Cl)(Cl)Cl)C2=CC=C(Br)C=C2)=CC=C3)C(=O)N1,20a,"2,2,2-trichloroethyl(1R)-1-(4-bromophenyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]cycloprop-2-ene-1-carboxylate","InChI=1S/C25H16BrCl3N2O6/c26-13-6-4-12(5-7-13)24(23(36)37-11-25(27,28)29)10-16(24)14-2-1-3-15-19(14)22(35)31(21(15)34)17-8-9-18(32)30-20(17)33/h1-7,10,17H,8-9,11H2,(H,30,32,33)/t17?,24-/m0/s1",GVMYAADQINSFHD-UCSBTNPJSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;CK1α;GSPT1;SALL4,"IKZF3: EC50 = 0.9 μM
CK1α: EC50 = 1.5 μM
GSPT1: EC50 = 4.3 μM
SALL4: EC50 = 0.56 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H16BrCl3N2O6,626.67,623.9257,4.10,-6.76,109.85,8,1,5,5,3,2,2,0,37,12,0,0
995,O=C1CCC(N2C(=O)C3=CC=C(C4=C[C@@]4(COOCC(Cl)(Cl)Cl)C4=CC=C(Br)C=C4)C=C3C2=O)C(=O)N1,22b,"5-[(3S)-3-(4-bromophenyl)-3-(2,2,2-trichloroethylperoxymethyl)cyclopropen-1-yl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione","InChI=1S/C25H18BrCl3N2O6/c26-15-4-2-14(3-5-15)24(11-36-37-12-25(27,28)29)10-18(24)13-1-6-16-17(9-13)23(35)31(22(16)34)19-7-8-20(32)30-21(19)33/h1-6,9-10,19H,7-8,11-12H2,(H,30,32,33)/t19?,24-/m1/s1",OGUXFJJARYZJDB-JKSFWZLDSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;CK1α;GSPT1;SALL4,"IKZF3: EC50 = 0.31 μM
CK1α: EC50 = 1.6 μM
GSPT1: EC50 = 1.4 μM
SALL4: EC50 = 2.4 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H18BrCl3N2O6,628.69,625.9414,4.50,-6.99,102.01,8,1,7,5,3,2,2,0,37,12,0,0
996,O=C1CCC(N2C(=O)C3=CC=C(C4=C[C@]4(C(=O)OCC(Cl)(Cl)Cl)C4=CC=C(Br)C=C4)C=C3C2=O)C(=O)N1,22a,"2,2,2-trichloroethyl(1S)-1-(4-bromophenyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]cycloprop-2-ene-1-carboxylate","InChI=1S/C25H16BrCl3N2O6/c26-14-4-2-13(3-5-14)24(23(36)37-11-25(27,28)29)10-17(24)12-1-6-15-16(9-12)22(35)31(21(15)34)18-7-8-19(32)30-20(18)33/h1-6,9-10,18H,7-8,11H2,(H,30,32,33)/t18?,24-/m0/s1",ITKMEHIIJSOLLY-LUTIACGYSA-N,Glutarimide,ThalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;CK1α;GSPT1;SALL4,"IKZF3: EC50 = 1.3 μM
CK1α: EC50 = 1.2 μM
GSPT1: EC50 = 1.1 μM
SALL4: EC50 = 3.6 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H16BrCl3N2O6,626.67,623.9257,4.10,-6.76,109.85,8,1,5,5,3,2,2,0,37,12,0,0
1054,O=C1CCC(N2CC3=C(C=C(NC(=O)C4=CN5C=CC=CC5=N4)C=C3)C2=O)C(=O)N1,QXG-6113,"N-[2-(2,6-dioxopiperidin-3-yl)-3-oxo-1H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-16(20(29)24-18)26-10-12-4-5-13(9-14(12)21(26)30)22-19(28)15-11-25-8-2-1-3-17(25)23-15/h1-5,8-9,11,16H,6-7,10H2,(H,22,28)(H,24,27,29)",UACDTPLSFIBBRI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10000 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 113 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1055,O=C1CCC(N2CC3=C(C=CC(CNC(=O)C4=CC=C(F)C=C4)=C3)C2=O)C(=O)N1,6,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-4-fluorobenzamide","InChI=1S/C21H18FN3O4/c22-15-4-2-13(3-5-15)19(27)23-10-12-1-6-16-14(9-12)11-25(21(16)29)17-7-8-18(26)24-20(17)28/h1-6,9,17H,7-8,10-11H2,(H,23,27)(H,24,26,28)",ZKKBMXPIWFMOKF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,Assay: FP; CRBN binding affinity = 1400 nM;,1,non-covalent,IKZF1,IKZF1: Dmax50 = 80 nM; Dmax = 57%(10 μM); (24 h),Unknown,CK1α,CK1α: DC50 > 10000 nM; Dmax = 23%(10 μM); (24 h),CRBN,Q96SW2,Cell: MOLM13; IC50 = 10000+ nM; 72 h,"Assay: NanoBRET; EC50 = 595 nM;(CK1α; 2 h)
Assay: NanoBRET; EC50 = 35 nM;(IKZF1; 2 h)",,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H18FN3O4,395.39,395.1281,1.52,-3.17,95.58,7,2,4,4,2,2,2,0,29,8,0,0
1056,O=C1CCC(N2CC3=C(C=CC(CNC(=O)C4=CN5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,QXG-6441,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H19N5O4/c28-19-7-6-17(21(30)25-19)27-11-14-9-13(4-5-15(14)22(27)31)10-23-20(29)16-12-26-8-2-1-3-18(26)24-16/h1-5,8-9,12,17H,6-7,10-11H2,(H,23,29)(H,25,28,30)",WTARIIKBLLAHEL-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10000 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H19N5O4,417.43,417.1437,1.03,-3.21,112.88,9,2,4,5,2,3,2,2,31,9,0,0
1058,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CC=C(F)C=C4)=C3)C2=O)C(=O)N1,7,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-4-fluorobenzamide","InChI=1S/C20H16FN3O4/c21-13-3-1-11(2-4-13)18(26)22-14-5-6-15-12(9-14)10-24(20(15)28)16-7-8-17(25)23-19(16)27/h1-6,9,16H,7-8,10H2,(H,22,26)(H,23,25,27)",XXJDKOPXHSTEEV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,30 μM,Assay: FP;CRBN binding affinity = 2100 nM;,1,non-covalent,CK1α,CK1α: DC50 = 10 nM; Dmax = 88%(10 μM); (24 h),Unknown,IKZF1,IKZF1: DC50 = 12 nM; Dmax = 12%(10 μM); (24 h),CRBN,Q96SW2,Cell: MOLM13; IC50 = 82 nM; 72 h,"Assay: NanoBRET; EC50 = 178 nM;(CK1α; 2 h)
Assay: NanoBRET; EC50 = 650 nM;(IKZF1; 2 h)",,"MDCKII Papp (nm/s) AB/BA: 2/5;
m/h LM t1/2 (h)(m/h = mouse/human): 10+/10+; 
m/h plasma stability t1/2 (h)d(m/h = mouse/human): 9/10",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H16FN3O4,381.36,381.1125,1.84,-3.48,95.58,7,2,3,4,2,2,2,0,28,8,0,0
1059,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CC=CC(C(F)(F)F)=C4)=C3)C2=O)C(=O)N1,17,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-(trifluoromethyl)benzamide","InChI=1S/C21H16F3N3O4/c22-21(23,24)13-3-1-2-11(8-13)18(29)25-14-4-5-15-12(9-14)10-27(20(15)31)16-6-7-17(28)26-19(16)30/h1-5,8-9,16H,6-7,10H2,(H,25,29)(H,26,28,30)",UCPCJPWMCSITTJ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 5 nM; Dmax = 90%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 17 nM; 72 h,Assay: NanoBRET; EC50 = 129 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H16F3N3O4,431.37,431.1093,2.72,-4.40,95.58,7,2,3,4,2,2,2,0,31,10,0,0
1060,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CC=CC(F)=C4)=C3)C2=O)C(=O)N1,16,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-fluorobenzamide","InChI=1S/C20H16FN3O4/c21-13-3-1-2-11(8-13)18(26)22-14-4-5-15-12(9-14)10-24(20(15)28)16-6-7-17(25)23-19(16)27/h1-5,8-9,16H,6-7,10H2,(H,22,26)(H,23,25,27)",IKDBDJNITQUCOU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,19 μM,,1,non-covalent,CK1α,CK1α: DC50 = 4 nM; Dmax = 88%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 28 nM; 72 h,Assay: NanoBRET; EC50 = 119 nM;(CK1α; 2 h),"CD1 Mice(Formulation: 5% v/v NMP; 5% v/v Solutol HS-15; 20% PEG 400; and 70% v/v normal saline.): 
IV(Dose 3 mg/kg): AUClast(ng·h/mL): 2049; C0/Cmax(ng/mL): 6447; t1/2 (h): 1.19; CL(mL/min/kg): 24; Vss(L/kg): 0.88;
PO(10 mg/kg ): AUClast(ng·h/mL): 2804; C0/Cmax(ng/mL): 1617; F%: 41.","MDCKII Papp (nm/s) AB/BA: 6/18;
m/h LM t1/2 (h)(m/h = mouse/human): 10+/10+; 
m/h plasma stability t1/2 (h)d(m/h = mouse/human): 10/10.6",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H16FN3O4,381.36,381.1125,1.84,-3.48,95.58,7,2,3,4,2,2,2,0,28,8,0,0
1061,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CC=CC=C4)=C3)C2=O)C(=O)N1,47,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]benzamide","InChI=1S/C20H17N3O4/c24-17-9-8-16(19(26)22-17)23-11-13-10-14(6-7-15(13)20(23)27)21-18(25)12-4-2-1-3-5-12/h1-7,10,16H,8-9,11H2,(H,21,25)(H,22,24,26)",CIVWAWPQWLUMPF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,77% degradation at 100 nM,G-loop_beta-hairpin,CK1α;IKZF1,"CK1α: 39% degradation at 100 nM
IKZF1: 52% degradation at 100 nM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C20H17N3O4,363.37,363.1219,1.70,-3.27,95.58,7,2,3,4,2,2,2,0,27,7,0,0
1061,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CC=CC=C4)=C3)C2=O)C(=O)N1,8,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]benzamide","InChI=1S/C20H17N3O4/c24-17-9-8-16(19(26)22-17)23-11-13-10-14(6-7-15(13)20(23)27)21-18(25)12-4-2-1-3-5-12/h1-7,10,16H,8-9,11H2,(H,21,25)(H,22,24,26)",CIVWAWPQWLUMPF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 12 nM; Dmax = 87%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 314 nM; 72 h,Assay: NanoBRET; EC50 = 127 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H17N3O4,363.37,363.1219,1.70,-3.27,95.58,7,2,3,4,2,2,2,0,27,7,0,0
1062,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN=C5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,QXG-1323,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]quinoxaline-2-carboxamide","InChI=1S/C22H17N5O4/c28-19-8-7-18(21(30)26-19)27-11-12-9-13(5-6-14(12)22(27)31)24-20(29)17-10-23-15-3-1-2-4-16(15)25-17/h1-6,9-10,18H,7-8,11H2,(H,24,29)(H,26,28,30)",RKVSIVQGWAFNJW-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 8.8 nM; Dmax = 80%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = 253 nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H17N5O4,415.41,415.1281,1.64,-3.77,121.36,9,2,3,5,2,3,2,1,31,9,0,0
1062,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN=C5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,5,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]quinoxaline-2-carboxamide","InChI=1S/C22H17N5O4/c28-19-8-7-18(21(30)26-19)27-11-12-9-13(5-6-14(12)22(27)31)24-20(29)17-10-23-15-3-1-2-4-16(15)25-17/h1-6,9-10,18H,7-8,11H2,(H,24,29)(H,26,28,30)",RKVSIVQGWAFNJW-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 8.8 ± 1.7 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H17N5O4,415.41,415.1281,1.64,-3.77,121.36,9,2,3,5,2,3,2,1,31,9,0,0
1063,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN=C5C=CC=CN45)=C3)C2=O)C(=O)N1,QXG-131-5,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-3-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-15(19(28)24-18)26-11-12-9-13(4-5-14(12)21(26)30)23-20(29)16-10-22-17-3-1-2-8-25(16)17/h1-5,8-10,15H,6-7,11H2,(H,23,29)(H,24,27,28)",VQGPONHHMUCOQM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 82 nM; Dmax = 83%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 376 nM; 72 h;
Cell: MOLM14; IC50 = 2219 nM; 72 h; Cell: MOLM13; EC50 = 396 nM; Cell: MOLM14; EC50 = 2669 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1063,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN=C5C=CC=CN45)=C3)C2=O)C(=O)N1,14,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-3-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-15(19(28)24-18)26-11-12-9-13(4-5-14(12)21(26)30)23-20(29)16-10-22-17-3-1-2-8-25(16)17/h1-5,8-10,15H,6-7,11H2,(H,23,29)(H,24,27,28)",VQGPONHHMUCOQM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 82 ± 13 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1064,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=C(Cl)C=CC5=N4)=C3)C2=O)C(=O)N1,QXG-131-8,"6-chloro-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16ClN5O4/c22-12-1-5-17-24-15(10-26(17)9-12)19(29)23-13-2-3-14-11(7-13)8-27(21(14)31)16-4-6-18(28)25-20(16)30/h1-3,5,7,9-10,16H,4,6,8H2,(H,23,29)(H,25,28,30)",BJBPGHNLQVARDK-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 1.3 nM; Dmax = 95%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 1066 nM; 72 h;
Cell: MOLM14; IC50 = 31 nM; 72 h; Cell: MOLM13; EC50 = 15 nM; Cell: MOLM14; EC50 = 31 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H16ClN5O4,437.84,437.0891,2.00,-4.18,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1064,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=C(Cl)C=CC5=N4)=C3)C2=O)C(=O)N1,23,"6-chloro-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16ClN5O4/c22-12-1-5-17-24-15(10-26(17)9-12)19(29)23-13-2-3-14-11(7-13)8-27(21(14)31)16-4-6-18(28)25-20(16)30/h1-3,5,7,9-10,16H,4,6,8H2,(H,23,29)(H,25,28,30)",BJBPGHNLQVARDK-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 1.3 ± 0.6 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H16ClN5O4,437.84,437.0891,2.00,-4.18,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1065,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=C(F)C=CC5=N4)=C3)C2=O)C(=O)N1,QXG-131-9,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16FN5O4/c22-12-1-5-17-24-15(10-26(17)9-12)19(29)23-13-2-3-14-11(7-13)8-27(21(14)31)16-4-6-18(28)25-20(16)30/h1-3,5,7,9-10,16H,4,6,8H2,(H,23,29)(H,25,28,30)",OWPGCXVVCWDQJC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 6.1 nM; Dmax = 90%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 58 nM; 72 h;
Cell: MOLM14; IC50 = 84 nM; 72 h; Cell: MOLM13; EC50 = 57 nM; Cell: MOLM14; EC50 = 82 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H16FN5O4,421.39,421.1186,1.49,-3.72,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1065,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=C(F)C=CC5=N4)=C3)C2=O)C(=O)N1,24,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16FN5O4/c22-12-1-5-17-24-15(10-26(17)9-12)19(29)23-13-2-3-14-11(7-13)8-27(21(14)31)16-4-6-18(28)25-20(16)30/h1-3,5,7,9-10,16H,4,6,8H2,(H,23,29)(H,25,28,30)",OWPGCXVVCWDQJC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 6.1 ± 1.3 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H16FN5O4,421.39,421.1186,1.49,-3.72,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1066,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC(C(F)(F)F)=CC5=N4)=C3)C2=O)C(=O)N1,QXG-131-4,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H16F3N5O4/c23-22(24,25)12-5-6-29-10-15(27-17(29)8-12)19(32)26-13-1-2-14-11(7-13)9-30(21(14)34)16-3-4-18(31)28-20(16)33/h1-2,5-8,10,16H,3-4,9H2,(H,26,32)(H,28,31,33)",VRDNFUSFZPRPEI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 1.6 nM; Dmax = 82%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 23 nM; 72 h;
Cell: MOLM14; IC50 = 33 nM; 72 h; Cell: MOLM13; EC50 = 23 nM; Cell: MOLM14; EC50 = 33 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H16F3N5O4,471.40,471.1154,2.37,-4.64,112.88,9,2,3,5,2,3,2,2,34,12,0,0
1067,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC(F)=CC5=N4)=C3)C2=O)C(=O)N1,QXG-131-10,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-fluoroimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16FN5O4/c22-12-5-6-26-10-15(24-17(26)8-12)19(29)23-13-1-2-14-11(7-13)9-27(21(14)31)16-3-4-18(28)25-20(16)30/h1-2,5-8,10,16H,3-4,9H2,(H,23,29)(H,25,28,30)",BZMWZADDRZLOHQ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 17.5 nM; Dmax = 88%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 126 nM; 72 h;
Cell: MOLM14; IC50 = 275 nM; 72 h; Cell: MOLM13; EC50 = 89 nM; Cell: MOLM14; EC50 = 273 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H16FN5O4,421.39,421.1186,1.49,-3.72,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1067,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC(F)=CC5=N4)=C3)C2=O)C(=O)N1,26,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-fluoroimidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H16FN5O4/c22-12-5-6-26-10-15(24-17(26)8-12)19(29)23-13-1-2-14-11(7-13)9-27(21(14)31)16-3-4-18(28)25-20(16)30/h1-2,5-8,10,16H,3-4,9H2,(H,23,29)(H,25,28,30)",BZMWZADDRZLOHQ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 17.5 ± 4.5 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H16FN5O4,421.39,421.1186,1.49,-3.72,112.88,9,2,3,5,2,3,2,2,31,10,0,0
1068,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,QXG-133-2,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]indolizine-2-carboxamide","InChI=1S/C22H18N4O4/c27-19-7-6-18(21(29)24-19)26-12-13-9-15(4-5-17(13)22(26)30)23-20(28)14-10-16-3-1-2-8-25(16)11-14/h1-5,8-11,18H,6-7,12H2,(H,23,28)(H,24,27,29)",YIUQFXABLLXKGK-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 87 nM; Dmax = 79%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 2140 nM; 72 h;
Cell: MOLM14; IC50 = 3685 nM; 72 h; Cell: MOLM13; EC50 = 2145 nM; Cell: MOLM14; EC50 = 3305 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H18N4O4,402.41,402.1328,1.95,-4.07,99.99,8,2,3,5,2,3,2,2,30,8,0,0
1068,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,17,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]indolizine-2-carboxamide","InChI=1S/C22H18N4O4/c27-19-7-6-18(21(29)24-19)26-12-13-9-15(4-5-17(13)22(26)30)23-20(28)14-10-16-3-1-2-8-25(16)11-14/h1-5,8-11,18H,6-7,12H2,(H,23,28)(H,24,27,29)",YIUQFXABLLXKGK-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 87 ± 23 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H18N4O4,402.41,402.1328,1.95,-4.07,99.99,8,2,3,5,2,3,2,2,30,8,0,0
1069,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,QXG-6442,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-16(20(29)24-18)26-10-12-9-13(4-5-14(12)21(26)30)22-19(28)15-11-25-8-2-1-3-17(25)23-15/h1-5,8-9,11,16H,6-7,10H2,(H,22,28)(H,24,27,29)",BRBLKCQDZREHRF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 5.7 nM; Dmax = 90%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 41 nM; 72 h;
Cell: MOLM14; IC50 = 111 nM; 72 h; ",,,"T1/2 in mimutes;
Human: 120+;
Mouse: 75.4","T1/2 in mimutes;
Human: 6-;
Mouse: 9",,https://doi.org/10.1101/2024.10.01.616159,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1069,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=CN5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,6(QXG-6442),"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-16(20(29)24-18)26-10-12-9-13(4-5-14(12)21(26)30)22-19(28)15-11-25-8-2-1-3-17(25)23-15/h1-5,8-9,11,16H,6-7,10H2,(H,22,28)(H,24,27,29)",BRBLKCQDZREHRF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 5.7 ± 1.7 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MOLM-13: IC50 = 41 nM,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1070,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NC=C5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,QXG-1322,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]isoquinoline-3-carboxamide","InChI=1S/C23H18N4O4/c28-20-8-7-19(22(30)26-20)27-12-15-9-16(5-6-17(15)23(27)31)25-21(29)18-10-13-3-1-2-4-14(13)11-24-18/h1-6,9-11,19H,7-8,12H2,(H,25,29)(H,26,28,30)",YMMHYGHNXAZOQF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10.0 nM; Dmax = 76.9%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = 250 nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C23H18N4O4,414.42,414.1328,2.25,-4.33,108.47,8,2,3,5,2,3,2,1,31,8,0,0
1070,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NC=C5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,3,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]isoquinoline-3-carboxamide","InChI=1S/C23H18N4O4/c28-20-8-7-19(22(30)26-20)27-12-15-9-16(5-6-17(15)23(27)31)25-21(29)18-10-13-3-1-2-4-14(13)11-24-18/h1-6,9-11,19H,7-8,12H2,(H,25,29)(H,26,28,30)",YMMHYGHNXAZOQF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 7.56 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C23H18N4O4,414.42,414.1328,2.25,-4.33,108.47,8,2,3,5,2,3,2,1,31,8,0,0
1071,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NC5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,QXG-133-6,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3aH-benzimidazole-2-carboxamide","InChI=1S/C21H17N5O4/c27-17-8-7-16(19(28)25-17)26-10-11-9-12(5-6-13(11)21(26)30)22-20(29)18-23-14-3-1-2-4-15(14)24-18/h1-6,9,14,16H,7-8,10H2,(H,22,29)(H,25,27,28)",ZBHGPYOZHLKXGR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 11.1 nM; Dmax = 84%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; Cell: MOLM13; EC50 = 114 nM; Cell: MOLM14; EC50 = 10000 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C21H17N5O4,403.40,403.1281,0.73,-2.05,120.30,9,2,3,5,4,1,3,0,30,9,0,0
1072,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,QXG-133-3,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]pyrazolo[1,5-a]pyridine-2-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-17(20(29)23-18)25-11-12-9-13(4-5-15(12)21(25)30)22-19(28)16-10-14-3-1-2-8-26(14)24-16/h1-5,8-10,17H,6-7,11H2,(H,22,28)(H,23,27,29)",WLWOVPHCBDZPAV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 4.7 nM; Dmax = 85%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 29 nM; 72 h;
Cell: MOLM14; IC50 = 81 nM; 72 h; Cell: MOLM13; EC50 = 42 nM; Cell: MOLM14; EC50 = 82 nM ",,,"T1/2 in mimutes;
Human: 65.4;
Mouse: 6.3","T1/2 in mimutes;
Human: 11;
Mouse: 111",,https://doi.org/10.1101/2024.10.01.616159,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1072,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=CC5=C4)=C3)C2=O)C(=O)N1,15,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]pyrazolo[1,5-a]pyridine-2-carboxamide","InChI=1S/C21H17N5O4/c27-18-7-6-17(20(29)23-18)25-11-12-9-13(4-5-15(12)21(25)30)22-19(28)16-10-14-3-1-2-8-26(14)24-16/h1-5,8-10,17H,6-7,11H2,(H,22,28)(H,23,27,29)",WLWOVPHCBDZPAV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 4.7 ± 0.5 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MOLM-13: IC50 = 29 nM,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H17N5O4,403.40,403.1281,1.35,-3.51,112.88,9,2,3,5,2,3,2,2,30,9,0,0
1073,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,QXG-133-4,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide","InChI=1S/C20H16N6O4/c27-16-7-6-14(18(28)23-16)25-10-11-9-12(4-5-13(11)20(25)30)21-19(29)17-22-15-3-1-2-8-26(15)24-17/h1-5,8-9,14H,6-7,10H2,(H,21,29)(H,23,27,28)",CHDBREXPALUJTD-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 61 nM; Dmax = 83%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 438 nM; 72 h;
Cell: MOLM14; IC50 = 1519 nM; 72 h; Cell: MOLM13; EC50 = 435 nM; Cell: MOLM14; EC50 = 1627 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C20H16N6O4,404.39,404.1233,0.74,-2.96,125.77,10,2,3,5,2,3,2,2,30,10,0,0
1073,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=CC5=N4)=C3)C2=O)C(=O)N1,18,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide","InChI=1S/C20H16N6O4/c27-16-7-6-14(18(28)23-16)25-10-11-9-12(4-5-13(11)20(25)30)21-19(29)17-22-15-3-1-2-8-26(15)24-17/h1-5,8-9,14H,6-7,10H2,(H,21,29)(H,23,27,28)",CHDBREXPALUJTD-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 61 ± 10 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C20H16N6O4,404.39,404.1233,0.74,-2.96,125.77,10,2,3,5,2,3,2,2,30,10,0,0
1074,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=NC5=C4)=C3)C2=O)C(=O)N1,QXG-133-5,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide","InChI=1S/C20H16N6O4/c27-17-5-4-15(19(29)23-17)25-10-11-8-12(2-3-13(11)20(25)30)22-18(28)14-9-16-21-6-1-7-26(16)24-14/h1-3,6-9,15H,4-5,10H2,(H,22,28)(H,23,27,29)",ZSHSKAUYLBAGAR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 61 nM; Dmax = 85%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 376 nM; 72 h;
Cell: MOLM14; IC50 = 1031 nM; 72 h; Cell: MOLM13; EC50 = 375 nM; Cell: MOLM14; EC50 = 1083 nM ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C20H16N6O4,404.39,404.1233,0.74,-2.96,125.77,10,2,3,5,2,3,2,2,30,10,0,0
1074,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4=NN5C=CC=NC5=C4)=C3)C2=O)C(=O)N1,19,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide","InChI=1S/C20H16N6O4/c27-17-5-4-15(19(29)23-17)25-10-11-8-12(2-3-13(11)20(25)30)22-18(28)14-9-16-21-6-1-7-26(16)24-14/h1-3,6-9,15H,4-5,10H2,(H,22,28)(H,23,27,29)",ZSHSKAUYLBAGAR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 61 ± 4 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C20H16N6O4,404.39,404.1233,0.74,-2.96,125.77,10,2,3,5,2,3,2,2,30,10,0,0
1075,O=C1CCC(N2CC3=C(C=CC(NC(=O)C4CCCCC4)=C3)C2=O)C(=O)N1,9,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]cyclohexanecarboxamide","InChI=1S/C20H23N3O4/c24-17-9-8-16(19(26)22-17)23-11-13-10-14(6-7-15(13)20(23)27)21-18(25)12-4-2-1-3-5-12/h6-7,10,12,16H,1-5,8-9,11H2,(H,21,25)(H,22,24,26)",XOQKZQJWZWHWDF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 23 nM; Dmax = 80%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 321 nM; 72 h,Assay: NanoBRET; EC50 = 137 nM;(CK1α; 2 h),,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H23N3O4,369.42,369.1689,1.97,-2.99,95.58,7,2,3,4,3,1,2,0,27,7,0,0
1078,O=C1CCC(N2CC3=C(C=CC(NC4=CN=C5C=CC=CN45)=C3)C2=O)C(=O)N1,20,"3-[6-(imidazo[1,2-a]pyridin-3-ylamino)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17N5O3/c26-18-7-6-15(19(27)23-18)25-11-12-9-13(4-5-14(12)20(25)28)22-17-10-21-16-3-1-2-8-24(16)17/h1-5,8-10,15,22H,6-7,11H2,(H,23,26,27)",BSDDYEGUSIPCLX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = >10000 nM; Dmax = 0%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 10000+ nM; 72 h,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H17N5O3,375.39,375.1331,1.84,-3.84,95.81,8,2,3,5,2,3,2,2,28,8,0,0
1079,O=C1CCC(N2CC3=C(C=CC(NC4=NC5=CC=CC=C5O4)=C3)C2=O)C(=O)N1,22,"3-[6-(1,3-benzoxazol-2-ylamino)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H16N4O4/c25-17-8-7-15(18(26)23-17)24-10-11-9-12(5-6-13(11)19(24)27)21-20-22-14-3-1-2-4-16(14)28-20/h1-6,9,15H,7-8,10H2,(H,21,22)(H,23,25,26)",WZMBCEZSOXUGFF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 4 nM; Dmax = 0%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 102 nM; 72 h,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H16N4O4,376.37,376.1172,2.33,-4.17,104.54,8,2,3,5,2,3,2,1,28,8,0,0
1080,O=C1CCC(N2CC3=C(C=CC(NC4=NN=C5C=CC=CC54)=C3)C2=O)C(=O)N1,21,"3-[6-(3aH-indazol-3-ylamino)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17N5O3/c26-17-8-7-16(19(27)22-17)25-10-11-9-12(5-6-13(11)20(25)28)21-18-14-3-1-2-4-15(14)23-24-18/h1-6,9,14,16H,7-8,10H2,(H,21,24)(H,22,26,27)",DFWFWUACKACIKL-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α: DC50 = 2 nM; Dmax = 89%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 22 nM; 72 h,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H17N5O3,375.39,375.1331,1.37,-2.53,103.23,8,2,2,5,4,1,3,0,28,8,0,0
1081,O=C1CCC(N2CC3=C(C=CC(NC4=NOC5C=C(F)C=CC45)=C3)C2=O)C(=O)N1,23,"3-[6-[(6-fluoro-3a,7a-dihydro-1,2-benzoxazol-3-yl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H17FN4O4/c21-11-1-3-14-16(8-11)29-24-18(14)22-12-2-4-13-10(7-12)9-25(20(13)28)15-5-6-17(26)23-19(15)27/h1-4,7-8,14-16H,5-6,9H2,(H,22,24)(H,23,26,27)",MSUPGNBTTYIWAD-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,26 μM,,1,non-covalent,CK1α,CK1α: DC50 = 4 nM; Dmax = 95%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 21 nM; 72 h,,"CD1 MiceFormulation: 5% v/v NMP; 5% v/v Solutol HS-15; and 90% v/v normal saline.): 
IV(Dose 3 mg/kg): AUClast(ng·h/mL): 911; C0/Cmax(ng/mL): 4236; t1/2 (h): 1.98; CL(mL/min/kg): 55; Vss(L/kg): 1.34;
PO(10 mg/kg ): AUClast(ng·h/mL): 306; C0/Cmax(ng/mL): 330; F%: 10.","MDCKII Papp (nm/s) AB/BA: 197/104;
m/h LM t1/2 (h)(m/h = mouse/human): 10+/ND; 
m/h plasma stability t1/2 (h)d(m/h = mouse/human): 17/ND",,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C20H17FN4O4,396.38,396.1234,1.61,-2.83,100.10,8,2,2,5,4,1,3,0,29,9,0,0
1082,O=C1CCC(N2CC3=C(C=CC(NC4=NOC5C=CC=CC45)=C3)C2=O)C(=O)N1,SJ3149,"3-[6-(3a,7a-dihydro-1,2-benzoxazol-3-ylamino)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H18N4O4/c25-17-8-7-15(19(26)22-17)24-10-11-9-12(5-6-13(11)20(24)27)21-18-14-3-1-2-4-16(14)28-23-18/h1-6,9,14-16H,7-8,10H2,(H,21,23)(H,22,25,26)",QEPOWTIIZZQQBU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,26 μM,,1,non-covalent,CK1α,CK1α: DC50 = 2 nM; Dmax = 95%(10 μM); (24 h),Unknown,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 13 nM; 72 h;CRBN FB IC50 = 844 nM,Assay: NanoBRET; EC50 = 10 nM;(CK1α; 2 h),"CD1 Mice(Formulation: 5% v/v NMP; 5% v/v Solutol HS-15; 20% PEG 400; and 70% v/v normal saline.): 
IV(Dose 3 mg/kg): AUClast(ng·h/mL): 832; C0/Cmax(ng/mL): 2705; t1/2 (h): 0.35; CL(mL/min/kg): 59; Vss(L/kg): 1.11;
PO(10 mg/kg ): AUClast(ng·h/mL): 264; C0/Cmax(ng/mL): 207; F%: 9.5;
PO(50 mg/kg ):  t1/2 (h): 2.57; tmax (h): 0.25;AUClast(ng·h/mL): 2848.12; C0/Cmax(ng/mL): 4740.05; F%: 12;
IP(50 mg/kg):  t1/2 (h): 3.08; tmax (h): 0.25;AUClast(ng·h/mL): 16983.57; C0/Cmax(ng/mL): 6683.49; F%: 74;","MDCKII Papp (nm/s) AB/BA: 30/22;
m/h LM t1/2 (h)(/h = mouse/human): 10+/ND; 
m/h plasma stability t1/2 (h)d(/h = mouse/human): 31/ND",,,https://doi.org/10.1038/s41467-024-44698-1,8G66,8G66: YOT,,C20H18N4O4,378.39,378.1328,1.31,-2.51,100.10,8,2,2,5,4,1,3,0,28,8,0,0
1087,O=C1CCC(N2CC3=C(C=CC=C3C3=C[C@@]3(COOCC(Cl)(Cl)Cl)C3=CC=C(Br)C=C3)C2=O)C(=O)N1,19b,"3-[7-[(3S)-3-(4-bromophenyl)-3-(2,2,2-trichloroethylperoxymethyl)cyclopropen-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H20BrCl3N2O5/c26-15-6-4-14(5-7-15)24(12-35-36-13-25(27,28)29)10-19(24)16-2-1-3-17-18(16)11-31(23(17)34)20-8-9-21(32)30-22(20)33/h1-7,10,20H,8-9,11-13H2,(H,30,32,33)/t20?,24-/m1/s1",JODTWQPBVOMTQI-PIFIWZBESA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;CK1α;GSPT1;SALL4,"IKZF3: EC50 = 0.11 μM
CK1α: EC50 = 1.5 μM
GSPT1: EC50 = 0.55 μM
SALL4: EC50 = 0.17 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H20BrCl3N2O5,614.71,611.9621,4.86,-7.24,84.94,7,1,7,5,3,2,2,0,36,11,0,0
1088,O=C1CCC(N2CC3=C(C=CC=C3C3=C[C@]3(C(=O)OCC(Cl)(Cl)Cl)C3=CC=C(Br)C=C3)C2=O)C(=O)N1,19a,"2,2,2-trichloroethyl(1R)-1-(4-bromophenyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]cycloprop-2-ene-1-carboxylate","InChI=1S/C25H18BrCl3N2O5/c26-14-6-4-13(5-7-14)24(23(35)36-12-25(27,28)29)10-18(24)15-2-1-3-16-17(15)11-31(22(16)34)19-8-9-20(32)30-21(19)33/h1-7,10,19H,8-9,11-12H2,(H,30,32,33)/t19?,24-/m0/s1",QJPRNMFEJIIKQS-WIIYFNMSSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF3;SALL4,"IKZF3: EC50 = 0.012 μM
SALL4: EC50 = 0.019 μM",Unknown,CK1α;GSPT1,"CK1α: EC50=0.17 μM
GSPT1: EC50=0.17 μM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H18BrCl3N2O5,612.69,609.9465,4.46,-7.01,92.78,7,1,5,5,3,2,2,0,36,11,0,0
1092,O=C1CCC(N2CC3=C(C=CC=C3CNC(=O)C3=CC=C(F)C=C3)C2=O)C(=O)N1,SJ7095,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]methyl]-4-fluorobenzamide","InChI=1S/C21H18FN3O4/c22-14-6-4-12(5-7-14)19(27)23-10-13-2-1-3-15-16(13)11-25(21(15)29)17-8-9-18(26)24-20(17)28/h1-7,17H,8-11H2,(H,23,27)(H,24,26,28)",QYERRCYEYNDQFV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF1;CK1α,"IKZF1: Assay: HiBiT; Cell: Jurkat; DC50 = 33 nM(4 h); Dmax = 83.7%(10 μM);
CK1α: Assay: HiBiT; Cell: HEK293; DC50 = 69 nM(4 h); Dmax = 82.2%(10 μM);",Unknown,,,CRBN,Q96SW2,CRBN FB IC50 = 1323 nM,Assay: NanoBRET; EC50 = 310 nM;(CK1α; 2 h),,,,,https://doi.org/10.1038/s41467-024-44698-1,,,,C21H18FN3O4,395.39,395.1281,1.52,-3.17,95.58,7,2,4,4,2,2,2,0,29,8,0,0
1092,O=C1CCC(N2CC3=C(C=CC=C3CNC(=O)C3=CC=C(F)C=C3)C2=O)C(=O)N1,5,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]methyl]-4-fluorobenzamide","InChI=1S/C21H18FN3O4/c22-14-6-4-12(5-7-14)19(27)23-10-13-2-1-3-15-16(13)11-25(21(15)29)17-8-9-18(26)24-20(17)28/h1-7,17H,8-11H2,(H,23,27)(H,24,26,28)",QYERRCYEYNDQFV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,Assay: FP; CRBN binding affinity = 1300 nM;,1,non-covalent,CK1α;IKZF1,"CK1α: DC50 = 28 nM; Dmax = 82%(10 μM); (24 h)
IKZF1: DC50 = 53 nM; Dmax = 84%(10 μM); (24 h)",Unknown,,,CRBN,Q96SW2,,"Assay: NanoBRET; EC50 = 260 nM;(CK1α; 2 h)
Assay: NanoBRET; EC50 = 120 nM;(IKZF1; 2 h)",,,,,https://doi.org/10.1021/acsmedchemlett.4c00250,,,,C21H18FN3O4,395.39,395.1281,1.52,-3.17,95.58,7,2,4,4,2,2,2,0,29,8,0,0
1093,O=C1CCC(N2CC3=C(C=CC=C3CNC(=O)C3=CC4=CC=CC=C4N=C3)C2=O)C(=O)N1,QXG-0663,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]methyl]quinoline-3-carboxamide","InChI=1S/C24H20N4O4/c29-21-9-8-20(23(31)27-21)28-13-18-15(5-3-6-17(18)24(28)32)11-26-22(30)16-10-14-4-1-2-7-19(14)25-12-16/h1-7,10,12,20H,8-9,11,13H2,(H,26,30)(H,27,29,31)",UNOMRBYIVAVAGY-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 138 nM; Dmax = 78%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 113 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C24H20N4O4,428.45,428.1485,1.93,-4.03,108.47,8,2,4,5,2,3,2,1,32,8,0,0
1093,O=C1CCC(N2CC3=C(C=CC=C3CNC(=O)C3=CC4=CC=CC=C4N=C3)C2=O)C(=O)N1,13,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]methyl]quinoline-3-carboxamide","InChI=1S/C24H20N4O4/c29-21-9-8-20(23(31)27-21)28-13-18-15(5-3-6-17(18)24(28)32)11-26-22(30)16-10-14-4-1-2-7-19(14)25-12-16/h1-7,10,12,20H,8-9,11,13H2,(H,26,30)(H,27,29,31)",UNOMRBYIVAVAGY-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 138 ± 36 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C24H20N4O4,428.45,428.1485,1.93,-4.03,108.47,8,2,4,5,2,3,2,1,32,8,0,0
1128,O=C1CCC(N2CC3=C(NC(=O)C4=CC5=CC=CC=C5N=C4)C=CC=C3C2=O)C(=O)N1,QXG-6433,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]quinoline-3-carboxamide","InChI=1S/C23H18N4O4/c28-20-9-8-19(22(30)26-20)27-12-16-15(23(27)31)5-3-7-18(16)25-21(29)14-10-13-4-1-2-6-17(13)24-11-14/h1-7,10-11,19H,8-9,12H2,(H,25,29)(H,26,28,30)",WUNKLUDRHNMFQZ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10000 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 40 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C23H18N4O4,414.42,414.1328,2.25,-4.33,108.47,8,2,3,5,2,3,2,1,31,8,0,0
1160,O=C1CCC(N2CC3=CC([C@H]4C[C@@]4(COOCC(Cl)(Cl)Cl)C4=CC=C(Br)C=C4)=CC=C3C2=O)C(=O)N1,15b,"3-[6-[(1R,2S)-2-(4-bromophenyl)-2-(2,2,2-trichloroethylperoxymethyl)cyclopropyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H22BrCl3N2O5/c26-17-4-2-16(3-5-17)24(12-35-36-13-25(27,28)29)10-19(24)14-1-6-18-15(9-14)11-31(23(18)34)20-7-8-21(32)30-22(20)33/h1-6,9,19-20H,7-8,10-13H2,(H,30,32,33)/t19-,20?,24-/m1/s1",DKLBYSSOZRYYMK-XARDSYGASA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α;SALL4,"CK1α: EC50 = 0.22 μM
SALL4: EC50 = 0.16 μM",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H22BrCl3N2O5,616.72,613.9778,4.95,-7.32,84.94,7,1,7,5,3,2,2,0,36,11,0,0
1161,O=C1CCC(N2CC3=CC(C4=C(Cl)N5C=CC=CC5=N4)=CC=C3C2=O)C(=O)N1,Compound 7,"3-[6-(3-chloroimidazo[1,2-a]pyridin-2-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C20H15ClN4O3/c21-18-17(22-15-3-1-2-8-24(15)18)11-4-5-13-12(9-11)10-25(20(13)28)14-6-7-16(26)23-19(14)27/h1-5,8-9,14H,6-7,10H2,(H,23,26,27)",IFOJCWBSMSYHLB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 10 nM; CK1α DC50: 10.6 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 > 10000nM;
Cell: SUDHL5; EC50 = 72nM;
Cell: Molm14; EC50 = 370nM;
Cell: NB-4; EC50 > 10000nM;
Cell: LoVo; EC50 > 10000nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C20H15ClN4O3,394.82,394.0833,2.42,-4.38,83.78,7,1,2,5,2,3,2,2,28,8,0,0
1162,O=C1CCC(N2CC3=CC(C4=C(NC5=CC=C6OCCOC6=C5)N5C=CC=CC5=N4)=CC=C3C2=O)C(=O)N1,Compound 2,"3-[6-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)imidazo[1,2-a]pyridin-2-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C28H23N5O5/c34-24-9-7-20(27(35)31-24)33-15-17-13-16(4-6-19(17)28(33)36)25-26(32-10-2-1-3-23(32)30-25)29-18-5-8-21-22(14-18)38-12-11-37-21/h1-6,8,10,13-14,20,29H,7,9,11-12,15H2,(H,31,34,35)",SPILVXJZWWFSPM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 28 nM; CK1α DC50: 4.0 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 > 10000nM;
Cell: SUDHL5; EC50 > 10000nM;
Cell: Molm14; EC50 > 10000nM;
Cell: NB-4; EC50 > 10000nM;
Cell:LoVo; EC50 > 10000nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C28H23N5O5,509.52,509.1699,3.28,-6.16,114.27,10,2,4,7,3,4,3,2,38,10,0,0
1163,O=C1CCC(N2CC3=CC(C4=C(NC5=CC=CC=C5)N5C=CC=CC5=N4)=CC=C3C2=O)C(=O)N1,Compound 9,"3-[6-(3-anilinoimidazo[1,2-a]pyridin-2-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C26H21N5O3/c32-22-12-11-20(25(33)29-22)31-15-17-14-16(9-10-19(17)26(31)34)23-24(27-18-6-2-1-3-7-18)30-13-5-4-8-21(30)28-23/h1-10,13-14,20,27H,11-12,15H2,(H,29,32,33)",UFQUXXZXMOACKI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 1.9 nM; CK1α DC50: 1.8 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 > 10000nM;
Cell: SUDHL5; EC50 = 72nM;
Cell: Molm14; EC50 > 10000nM;
Cell: NB-4; EC50 > 10000nM;
Cell: LoVo; EC50 > 10000nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C26H21N5O3,451.49,451.1644,3.51,-6.18,95.81,8,2,4,6,2,4,2,2,34,8,0,0
1164,O=C1CCC(N2CC3=CC(C4=C(NC56CC7CC(CC(C7)C5)C6)N5C=CC=CC5=N4)=CC=C3C2=O)C(=O)N1,Compound 10,"3-[6-[3-(1-adamantylamino)imidazo[1,2-a]pyridin-2-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C30H31N5O3/c36-25-7-6-23(28(37)32-25)35-16-21-12-20(4-5-22(21)29(35)38)26-27(34-8-2-1-3-24(34)31-26)33-30-13-17-9-18(14-30)11-19(10-17)15-30/h1-5,8,12,17-19,23,33H,6-7,9-11,13-16H2,(H,32,36,37)",BDZWATYRORWZMU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,WEE1;CK1α,"WEE1 DC50: 1.5 nM; CK1α DC50: 1.6 nM
Western WEE1 and CK1α degradation under in MOLT4 cells",G-loop_beta-hairpin,,,CRBN,Q96SW2,"Assay: Cell Viability; 
Cell: Jurkat; EC50 = 54nM;
Cell: SUDHL5; EC50 = 23nM;
Cell: Molm14; EC50 = 35nM;
Cell: NB-4; EC50 = 26nM;
Cell: LoVo; EC50 = 40nM",,,,,,https://doi.org/10.1021/jacs.4c06127,,,,C30H31N5O3,509.61,509.2427,4.14,-6.27,95.81,8,2,4,9,6,3,2,2,38,8,0,4
1165,O=C1CCC(N2CC3=CC(C4=C[C@@]4(COOCC(Cl)(Cl)Cl)C4=CC=C(Br)C=C4)=CC=C3C2=O)C(=O)N1,21b,"3-[6-[(3S)-3-(4-bromophenyl)-3-(2,2,2-trichloroethylperoxymethyl)cyclopropen-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C25H20BrCl3N2O5/c26-17-4-2-16(3-5-17)24(12-35-36-13-25(27,28)29)10-19(24)14-1-6-18-15(9-14)11-31(23(18)34)20-7-8-21(32)30-22(20)33/h1-6,9-10,20H,7-8,11-13H2,(H,30,32,33)/t20?,24-/m1/s1",HNNUQHAIWLOKQD-PIFIWZBESA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,SALL4,SALL4: EC50 = 0.075 μM,Unknown,IKZF3;CK1α;GSPT1,"IKZF3: EC50=4.8 μM
CK1α: EC50=0.25 μM
GSPT1: EC50=3.3 μM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acsmedchemlett.4c00297,,,,C25H20BrCl3N2O5,614.71,611.9621,4.86,-7.24,84.94,7,1,7,5,3,2,2,0,36,11,0,0
1168,O=C1CCC(N2CC3=CC(C4=CC5=C(C=CC=C5)N=C4)=CC=C3C2=O)C(=O)N1,QXG-0632,"3-(3-oxo-6-quinolin-3-yl-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C22H17N3O3/c26-20-8-7-19(21(27)24-20)25-12-16-9-13(5-6-17(16)22(25)28)15-10-14-3-1-2-4-18(14)23-11-15/h1-6,9-11,19H,7-8,12H2,(H,24,26,27)",DBTUFNLLQDVGDB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 46.8 nM; Dmax = 60.3%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 1639 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,"T1/2 in mimutes
Human: 120+; 
Mouse:65.6"," Clint in μ/min/mg
Human:  6-;
Mouse:11",,https://doi.org/10.1101/2024.10.01.616159,,,,C22H17N3O3,371.40,371.1270,2.66,-4.53,79.37,6,1,2,5,2,3,2,1,28,6,0,0
1168,O=C1CCC(N2CC3=CC(C4=CC5=C(C=CC=C5)N=C4)=CC=C3C2=O)C(=O)N1,2(QXG-0632),"3-(3-oxo-6-quinolin-3-yl-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C22H17N3O3/c26-20-8-7-19(21(27)24-20)25-12-16-9-13(5-6-17(16)22(25)28)15-10-14-3-1-2-4-18(14)23-11-15/h1-6,9-11,19H,7-8,12H2,(H,24,26,27)",DBTUFNLLQDVGDB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 46.8 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MOLM-13: IC50 = 2.4 μM,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H17N3O3,371.40,371.1270,2.66,-4.53,79.37,6,1,2,5,2,3,2,1,28,6,0,0
1169,O=C1CCC(N2CC3=CC(C4=NC=C5C=CC=CC5=C4)=CC=C3C2=O)C(=O)N1,QXG-6029,"3-(6-isoquinolin-3-yl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C22H17N3O3/c26-20-8-7-19(21(27)24-20)25-12-16-9-14(5-6-17(16)22(25)28)18-10-13-3-1-2-4-15(13)11-23-18/h1-6,9-11,19H,7-8,12H2,(H,24,26,27)",UYLCECOIORPNBC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10.0 nM; Dmax = 86.0%,G-loop_beta-hairpin,WEE1,Assay: WB; DC50 = 43.0 nM; Dmax = 80.0%,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 34 nM; 72 h;
Cell: MOLM14; IC50 = 230 nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C22H17N3O3,371.40,371.1270,2.66,-4.53,79.37,6,1,2,5,2,3,2,1,28,6,0,0
1169,O=C1CCC(N2CC3=CC(C4=NC=C5C=CC=CC5=C4)=CC=C3C2=O)C(=O)N1,1(QXG-0629),"3-(6-isoquinolin-3-yl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C22H17N3O3/c26-20-8-7-19(21(27)24-20)25-12-16-9-14(5-6-17(16)22(25)28)18-10-13-3-1-2-4-15(13)11-23-18/h1-6,9-11,19H,7-8,12H2,(H,24,26,27)",UYLCECOIORPNBC-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 10 nM,G-loop_beta-hairpin,GSPT1;WEE1;IKZF2,WEE1: DC50 = 43 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H17N3O3,371.40,371.1270,2.66,-4.53,79.37,6,1,2,5,2,3,2,1,28,6,0,0
1170,O=C1CCC(N2CC3=CC(C4=NC5=C(Br)C=NN5C=C4)=CC=C3C2=O)C(=O)N1,LC-02-047-P1,"3-[6-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C19H14BrN5O3/c20-13-8-21-25-6-5-14(22-17(13)25)10-1-2-12-11(7-10)9-24(19(12)28)15-3-4-16(26)23-18(15)27/h1-2,5-8,15H,3-4,9H2,(H,23,26,27)",YEFAKXFTUMESCG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 14 nM; Dmax = 86%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 13 nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C19H14BrN5O3,440.26,439.0280,1.92,-4.17,96.67,8,1,2,5,2,3,2,2,28,9,0,0
1171,O=C1CCC(N2CC3=CC(C4=NC5=C(Cl)C(CN6CCOCC6)=NN5C=C4)=CC=C3C2=O)C(=O)N1,dCK1α-2,"3-[6-[3-chloro-2-(morpholin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-5-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C24H23ClN6O4/c25-21-18(13-29-7-9-35-10-8-29)28-31-6-5-17(26-22(21)31)14-1-2-16-15(11-14)12-30(24(16)34)19-3-4-20(32)27-23(19)33/h1-2,5-6,11,19H,3-4,7-10,12-13H2,(H,27,32,33)",XIQNTJXNMQHUHV-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 146 nM; Dmax = 84%,G-loop_beta-hairpin,,,CRBN,Q96SW2,-,,,"Mouse; IV;  5mg/kg;Tmax: 0.0833 h; T1/2: 0.98; Cmax: 3020 mg/ml; AUC0-t: 1597 hr*ng/ml; MRT0-t: 0.478 h; %F: 0;
PO;  10mg/kg;Tmax: 0.333 h; T1/2: 1.48; Cmax: 883 mg/ml; AUC0-t: 1056 hr*ng/ml; MRT0-t: 1.30 h; %F: 33%;",,,https://doi.org/10.1021/jacsau.4c00762,,,,C24H23ClN6O4,494.94,494.1469,1.64,-3.95,109.14,10,1,4,6,3,3,3,2,35,11,0,0
1172,O=C1CCC(N2CC3=CC(C4=NC5=C(Cl)C=NN5C=C4)=CC=C3C2=O)C(=O)N1,LC-04-087,"3-[6-(3-chloropyrazolo[1,5-a]pyrimidin-5-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione","InChI=1S/C19H14ClN5O3/c20-13-8-21-25-6-5-14(22-17(13)25)10-1-2-12-11(7-10)9-24(19(12)28)15-3-4-16(26)23-18(15)27/h1-2,5-8,15H,3-4,9H2,(H,23,26,27)",VLQCOELYHBYNNI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 12 nM; Dmax = 90%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 8 nM; 72 h; Cell: MV4-11; IC50 = 2 nM; 72 h; Cell: Kasumal; IC50 = 584 nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C19H14ClN5O3,395.81,395.0785,1.81,-3.82,96.67,8,1,2,5,2,3,2,2,28,9,0,0
1173,O=C1CCC(N2CC3=CC(C4=NC5=CC=NN5C=C4)=CC=C3C2=O)C(=O)N1,LC-04-075,"3-(3-oxo-6-pyrazolo[1,5-a]pyrimidin-5-yl-1H-isoindol-2-yl)piperidine-2,6-dione","InChI=1S/C19H15N5O3/c25-17-4-3-15(18(26)22-17)23-10-12-9-11(1-2-13(12)19(23)27)14-6-8-24-16(21-14)5-7-20-24/h1-2,5-9,15H,3-4,10H2,(H,22,25,26)",JFGCAFRJJYPKRT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 141 nM; Dmax = 79%,G-loop_beta-hairpin,,,CRBN,Q96SW2,Cell: MOLM13; IC50 = 100+ nM; 72 h,,,,,,https://doi.org/10.1021/jacsau.4c00762,,,,C19H15N5O3,361.36,361.1175,1.16,-3.15,96.67,8,1,2,5,2,3,2,2,27,8,0,0
1180,O=C1CCC(N2CC3=CC(CNC(=O)C4=CC5=CC=CC=C5N=C4)=CC=C3C2=O)C(=O)N1,QXG-6431,"N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]quinoline-3-carboxamide","InChI=1S/C24H20N4O4/c29-21-8-7-20(23(31)27-21)28-13-17-9-14(5-6-18(17)24(28)32)11-26-22(30)16-10-15-3-1-2-4-19(15)25-12-16/h1-6,9-10,12,20H,7-8,11,13H2,(H,26,30)(H,27,29,31)",CHCMXRWIWJYZNW-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 10000 nM; Dmax = 0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = - nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,,,,https://doi.org/10.1101/2024.10.01.616159,,,,C24H20N4O4,428.45,428.1485,1.93,-4.03,108.47,8,2,4,5,2,3,2,1,32,8,0,0
1191,O=C1CCC(N2CC3=CC(NC(=O)C4=CC(C(=O)C5=CC=CC=C5)=CC=C4)=CC=C3C2=O)C(=O)N1,53,"3-benzoyl-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]benzamide","InChI=1S/C27H21N3O5/c31-23-12-11-22(26(34)29-23)30-15-19-14-20(9-10-21(19)27(30)35)28-25(33)18-8-4-7-17(13-18)24(32)16-5-2-1-3-6-16/h1-10,13-14,22H,11-12,15H2,(H,28,33)(H,29,31,34)",BHLNTYNHSHZTQT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,83% degradation at 100 nM,G-loop_beta-hairpin,CK1α;IKZF1,"CK1α: 64% degradation at 100 nM
IKZF1: 60% degradation at 100 nM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C27H21N3O5,467.48,467.1481,2.93,-5.02,112.65,8,2,5,5,2,3,2,0,35,8,0,0
1192,O=C1CCC(N2CC3=CC(NC(=O)C4=CC(OC5=CC=CC=C5)=CC=C4)=CC=C3C2=O)C(=O)N1,51,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3-phenoxybenzamide","InChI=1S/C26H21N3O5/c30-23-12-11-22(25(32)28-23)29-15-17-13-18(9-10-21(17)26(29)33)27-24(31)16-5-4-8-20(14-16)34-19-6-2-1-3-7-19/h1-10,13-14,22H,11-12,15H2,(H,27,31)(H,28,30,32)",DTGOZYNEQILPSF-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,74% degradation at 100 nM,G-loop_beta-hairpin,CK1α;IKZF1,"CK1α: 58% degradation at 100 nM
IKZF1: 62% degradation at 100 nM",CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H21N3O5,455.47,455.1481,3.49,-5.36,104.81,8,2,5,5,2,3,2,0,34,8,0,0
1193,O=C1CCC(N2CC3=CC(NC(=O)C4=CC=C(OC5=CC=CC=C5)C=C4)=CC=C3C2=O)C(=O)N1,52,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-4-phenoxybenzamide","InChI=1S/C26H21N3O5/c30-23-13-12-22(25(32)28-23)29-15-17-14-18(8-11-21(17)26(29)33)27-24(31)16-6-9-20(10-7-16)34-19-4-2-1-3-5-19/h1-11,14,22H,12-13,15H2,(H,27,31)(H,28,30,32)",UNTZICXADQTICO-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,78% degradation at 100 nM,G-loop_beta-hairpin,CK1α,61% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H21N3O5,455.47,455.1481,3.49,-5.36,104.81,8,2,5,5,2,3,2,0,34,8,0,0
1194,O=C1CCC(N2CC3=CC(NC(=O)C4=CC=C(SC5=CC=CC=C5)C=C4)=CC=C3C2=O)C(=O)N1,71,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-4-phenylsulfanylbenzamide","InChI=1S/C26H21N3O4S/c30-23-13-12-22(25(32)28-23)29-15-17-14-18(8-11-21(17)26(29)33)27-24(31)16-6-9-20(10-7-16)34-19-4-2-1-3-5-19/h1-11,14,22H,12-13,15H2,(H,27,31)(H,28,30,32)",YTBICKXJMTXDLY-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,67% degradation at 100 nM,G-loop_beta-hairpin,CK1α,57% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C26H21N3O4S,471.54,471.1253,3.85,-5.84,95.58,7,2,5,5,2,3,2,0,34,8,0,0
1195,O=C1CCC(N2CC3=CC(NC(=O)C4=CC=C5C=CC=CC5=C4)=CC=C3C2=O)C(=O)N1,9,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]naphthalene-2-carboxamide","InChI=1S/C24H19N3O4/c28-21-10-9-20(23(30)26-21)27-13-17-12-18(7-8-19(17)24(27)31)25-22(29)16-6-5-14-3-1-2-4-15(14)11-16/h1-8,11-12,20H,9-10,13H2,(H,25,29)(H,26,28,30)",BQQPXXCYYWRWRG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,"MOLM-13 cells were treated with 25 μM compound: western blot relative ratio = 0.27;
80% degradation at 100 nM",G-loop_beta-hairpin,CK1α,65% degradation at 100 nM,CRBN,Q96SW2,,,,Liver Microsome Metabolic Stability Assay: mouse: t1/2 > 255 min ; CLint < 5.4 μL/min/mg; human: t1/2 >255 min; CLint < 5.4 μL/min/mg,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H19N3O4,413.43,413.1376,2.85,-4.89,95.58,7,2,3,5,2,3,2,0,31,7,0,0
1195,O=C1CCC(N2CC3=CC(NC(=O)C4=CC=C5C=CC=CC5=C4)=CC=C3C2=O)C(=O)N1,DEG-9,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]naphthalene-2-carboxamide","InChI=1S/C24H19N3O4/c28-21-10-9-20(23(30)26-21)27-13-17-12-18(7-8-19(17)24(27)31)25-22(29)16-6-5-14-3-1-2-4-15(14)11-16/h1-8,11-12,20H,9-10,13H2,(H,25,29)(H,26,28,30)",BQQPXXCYYWRWRG-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2: 64% degradation at 100 nM;
CK1α: 96% degradation at 100 nM",G-loop_beta-hairpin,IKZF1;IKZF3;IKZF4,"IKZF1: 29% degradation at 100 nM;
IKZF3: 41% degradation at 100 nM;
IKZF4: 43% degradation at 100 nM",CRBN,Q96SW2,Cell: MOLM-13; IC50 = 367 nM,,,,,,https://doi.org/10.1016/j.ccell.2023.02.010,,,,C24H19N3O4,413.43,413.1376,2.85,-4.89,95.58,7,2,3,5,2,3,2,0,31,7,0,0
1196,O=C1CCC(N2CC3=CC(NC(=O)C4=CC=C5N=CSC5=C4)=CC=C3C2=O)C(=O)N1,61,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1,3-benzothiazole-6-carboxamide","InChI=1S/C21H16N4O4S/c26-18-6-5-16(20(28)24-18)25-9-12-7-13(2-3-14(12)21(25)29)23-19(27)11-1-4-15-17(8-11)30-10-22-15/h1-4,7-8,10,16H,5-6,9H2,(H,23,27)(H,24,26,28)",BUKXXJVKMXZXHH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,42% degradation at 100 nM,G-loop_beta-hairpin,CK1α,33% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C21H16N4O4S,420.45,420.0892,2.31,-4.41,108.47,8,2,3,5,2,3,2,1,30,9,0,0
1198,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=C(C=C4)CCCC5)=CC=C3C2=O)C(=O)N1,56,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-5,6,7,8-tetrahydronaphthalene-2-carboxamide","InChI=1S/C24H23N3O4/c28-21-10-9-20(23(30)26-21)27-13-17-12-18(7-8-19(17)24(27)31)25-22(29)16-6-5-14-3-1-2-4-15(14)11-16/h5-8,11-12,20H,1-4,9-10,13H2,(H,25,29)(H,26,28,30)",NYWWYHLFJSMTAB-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,74% degradation at 100 nM,G-loop_beta-hairpin,CK1α,51% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H23N3O4,417.47,417.1689,2.58,-4.21,95.58,7,2,3,5,3,2,2,0,31,7,0,0
1199,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=C(C=C4)OC=C5)=CC=C3C2=O)C(=O)N1,60,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1-benzofuran-5-carboxamide","InChI=1S/C22H17N3O5/c26-19-6-4-17(21(28)24-19)25-11-14-10-15(2-3-16(14)22(25)29)23-20(27)13-1-5-18-12(9-13)7-8-30-18/h1-3,5,7-10,17H,4,6,11H2,(H,23,27)(H,24,26,28)",WOCJTQKFCZJBHU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,61% degradation at 100 nM,G-loop_beta-hairpin,CK1α,50% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C22H17N3O5,403.39,403.1168,2.45,-4.40,108.72,8,2,3,5,2,3,2,1,30,8,0,0
1200,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=C(C=C4)OCCO5)=CC=C3C2=O)C(=O)N1,54,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide","InChI=1S/C22H19N3O6/c26-19-6-4-16(21(28)24-19)25-11-13-9-14(2-3-15(13)22(25)29)23-20(27)12-1-5-17-18(10-12)31-8-7-30-17/h1-3,5,9-10,16H,4,6-8,11H2,(H,23,27)(H,24,26,28)",MLWAXSSCWMTYTR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,38% degradation at 100 nM,G-loop_beta-hairpin,CK1α;IKZF1,36% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C22H19N3O6,421.41,421.1274,1.47,-3.20,114.04,9,2,3,5,3,2,3,0,31,9,0,0
1201,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=C(C=C4)OCO5)=CC=C3C2=O)C(=O)N1,55,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1,3-benzodioxole-5-carboxamide","InChI=1S/C21H17N3O6/c25-18-6-4-15(20(27)23-18)24-9-12-7-13(2-3-14(12)21(24)28)22-19(26)11-1-5-16-17(8-11)30-10-29-16/h1-3,5,7-8,15H,4,6,9-10H2,(H,22,26)(H,23,25,27)",QFCPONCMDMLLOZ-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,49% degradation at 100 nM,G-loop_beta-hairpin,CK1α,36% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C21H17N3O6,407.38,407.1117,1.43,-3.08,114.04,9,2,3,5,3,2,3,0,30,9,0,0
1202,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=C(C=CC=C5)O4)=CC=C3C2=O)C(=O)N1,59,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1-benzofuran-2-carboxamide","InChI=1S/C22H17N3O5/c26-19-8-7-16(20(27)24-19)25-11-13-9-14(5-6-15(13)22(25)29)23-21(28)18-10-12-3-1-2-4-17(12)30-18/h1-6,9-10,16H,7-8,11H2,(H,23,28)(H,24,26,27)",GRDLGPVCCSHERU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,80% degradation at 100 nM,G-loop_beta-hairpin,CK1α,62% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C22H17N3O5,403.39,403.1168,2.45,-4.40,108.72,8,2,3,5,2,3,2,1,30,8,0,0
1203,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC(Br)=CC(Br)=C5OC4)=CC=C3C2=O)C(=O)N1,81,"6,8-dibromo-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2H-chromene-3-carboxamide","InChI=1S/C23H17Br2N3O5/c24-14-6-11-5-13(10-33-20(11)17(25)8-14)21(30)26-15-1-2-16-12(7-15)9-28(23(16)32)18-3-4-19(29)27-22(18)31/h1-2,5-8,18H,3-4,9-10H2,(H,26,30)(H,27,29,31)",QKPKDXGPDMVCIR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,49% degradation at 100 nM,G-loop_beta-hairpin,CK1α,47% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C23H17Br2N3O5,575.21,572.9535,3.39,-5.98,104.81,8,2,3,5,3,2,3,0,33,10,0,0
1204,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=C(Br)C=C5OC4)=CC=C3C2=O)C(=O)N1,73,"7-bromo-N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2H-chromene-3-carboxamide","InChI=1S/C23H18BrN3O5/c24-15-2-1-12-7-14(11-32-19(12)9-15)21(29)25-16-3-4-17-13(8-16)10-27(23(17)31)18-5-6-20(28)26-22(18)30/h1-4,7-9,18H,5-6,10-11H2,(H,25,29)(H,26,28,30)",PDLMVPIBYOAMMI-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,80% degradation at 100 nM,G-loop_beta-hairpin,CK1α,62% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C23H18BrN3O5,496.32,495.0430,2.62,-4.59,104.81,8,2,3,5,3,2,3,0,32,9,0,0
1205,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=C(C(F)(F)F)C=C5OC4)=CC=C3C2=O)C(=O)N1,79,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-(trifluoromethyl)-2H-chromene-3-carboxamide","InChI=1S/C24H18F3N3O5/c25-24(26,27)15-2-1-12-7-14(11-35-19(12)9-15)21(32)28-16-3-4-17-13(8-16)10-30(23(17)34)18-5-6-20(31)29-22(18)33/h1-4,7-9,18H,5-6,10-11H2,(H,28,32)(H,29,31,33)",BTYAHFGEMWWMRT-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,75% degradation at 100 nM,G-loop_beta-hairpin,CK1α,66% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H18F3N3O5,485.42,485.1199,2.88,-4.71,104.81,8,2,3,5,3,2,3,0,35,11,0,0
1206,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=C(O)C=C5C=C4)=CC=C3C2=O)C(=O)N1,40,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-6-hydroxynaphthalene-2-carboxamide","InChI=1S/C24H19N3O5/c28-18-5-3-13-9-15(2-1-14(13)11-18)22(30)25-17-4-6-19-16(10-17)12-27(24(19)32)20-7-8-21(29)26-23(20)31/h1-6,9-11,20,28H,7-8,12H2,(H,25,30)(H,26,29,31)",PIJSUKFVTTZUBA-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,60% degradation at 100 nM,G-loop_beta-hairpin,CK1α,55% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H19N3O5,429.43,429.1325,2.56,-4.39,115.81,8,3,3,5,2,3,2,0,32,8,0,0
1207,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=C(OC(F)(F)F)C=C5OC4)=CC=C3C2=O)C(=O)N1,78,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-7-(trifluoromethoxy)-2H-chromene-3-carboxamide","InChI=1S/C24H18F3N3O6/c25-24(26,27)36-16-3-1-12-7-14(11-35-19(12)9-16)21(32)28-15-2-4-17-13(8-15)10-30(23(17)34)18-5-6-20(31)29-22(18)33/h1-4,7-9,18H,5-6,10-11H2,(H,28,32)(H,29,31,33)",XSQZMTIDRIDBJN-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,85% degradation at 100 nM,G-loop_beta-hairpin,CK1α,58% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C24H18F3N3O6,501.42,501.1148,2.76,-4.54,114.04,9,2,4,5,3,2,3,0,36,12,0,0
1209,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=CC=C5N=C4)=CC=C3C2=O)C(=O)N1,QXG-6432,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]quinoline-3-carboxamide","InChI=1S/C23H18N4O4/c28-20-8-7-19(22(30)26-20)27-12-15-10-16(5-6-17(15)23(27)31)25-21(29)14-9-13-3-1-2-4-18(13)24-11-14/h1-6,9-11,19H,7-8,12H2,(H,25,29)(H,26,28,30)",GLIBRRMRYUZHHU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,Assay: WB; DC50 = 8.8 nM; Dmax = 88.0%,G-loop_beta-hairpin,,,CRBN,Q96SW2,"Cell: MOLM13; IC50 = 174 nM; 72 h;
Cell: MOLM14; IC50 = - nM; 72 h; ",,,"T1/2 in mimutes;
Human: 23.4;
Mouse: 120+","T1/2 in mimutes;
Human: 30;
Mouse: 6-",,https://doi.org/10.1101/2024.10.01.616159,,,,C23H18N4O4,414.42,414.1328,2.25,-4.33,108.47,8,2,3,5,2,3,2,1,31,8,0,0
1209,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=CC=C5N=C4)=CC=C3C2=O)C(=O)N1,4,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]quinoline-3-carboxamide","InChI=1S/C23H18N4O4/c28-20-8-7-19(22(30)26-20)27-12-15-10-16(5-6-17(15)23(27)31)25-21(29)14-9-13-3-1-2-4-18(13)24-11-14/h1-6,9-11,19H,7-8,12H2,(H,25,29)(H,26,28,30)",GLIBRRMRYUZHHU-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 79 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C23H18N4O4,414.42,414.1328,2.25,-4.33,108.47,8,2,3,5,2,3,2,1,31,8,0,0
1210,O=C1CCC(N2CC3=CC(NC(=O)C4=CC5=CC=CC=C5OC4)=CC=C3C2=O)C(=O)N1,57,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2H-chromene-3-carboxamide","InChI=1S/C23H19N3O5/c27-20-8-7-18(22(29)25-20)26-11-14-10-16(5-6-17(14)23(26)30)24-21(28)15-9-13-3-1-2-4-19(13)31-12-15/h1-6,9-10,18H,7-8,11-12H2,(H,24,28)(H,25,27,29)",UIFPBNRHYJGQSS-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,84% degradation at 100 nM,G-loop_beta-hairpin,CK1α,68% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C23H19N3O5,417.42,417.1325,1.86,-3.58,104.81,8,2,3,5,3,2,3,0,31,8,0,0
1211,O=C1CCC(N2CC3=CC(NC(=O)C4=COC5=C(C=CC=C5)O4)=CC=C3C2=O)C(=O)N1,58,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1,4-benzodioxine-3-carboxamide","InChI=1S/C22H17N3O6/c26-19-8-7-15(20(27)24-19)25-10-12-9-13(5-6-14(12)22(25)29)23-21(28)18-11-30-16-3-1-2-4-17(16)31-18/h1-6,9,11,15H,7-8,10H2,(H,23,28)(H,24,26,27)",NIKSBFIHOGSQSH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2,71% degradation at 100 nM,G-loop_beta-hairpin,CK1α,46% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C22H17N3O6,419.39,419.1117,1.70,-3.35,114.04,9,2,3,5,3,2,3,0,31,9,0,0
1213,O=C1CCC(N2CC3=CC(NC(=O)CC4=CC=CC5=CC=CC=C45)=CC=C3C2=O)C(=O)N1,49,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-2-naphthalen-1-ylacetamide","InChI=1S/C25H21N3O4/c29-22-11-10-21(24(31)27-22)28-14-17-12-18(8-9-20(17)25(28)32)26-23(30)13-16-6-3-5-15-4-1-2-7-19(15)16/h1-9,12,21H,10-11,13-14H2,(H,26,30)(H,27,29,31)",RYIPWXZJIZGEKX-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,IKZF2;IKZF1,"IKZF2: 92% degradation at 100 nM;
IKZF1: 97% degradation at 100 nM",G-loop_beta-hairpin,CK1α,64% degradation at 100 nM,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.3c01736,,,,C25H21N3O4,427.46,427.1532,2.78,-4.87,95.58,7,2,4,5,2,3,2,0,32,7,0,0
1288,CC1=CC=C(NC(=O)NCC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CS2)C=C1Cl,BTX306,"1-(3-chloro-4-methylphenyl)-3-[[5-(2,6-dioxopiperidin-3-yl)-6-oxo-4H-thieno[3,4-c]pyrrol-3-yl]methyl]urea","InChI=1S/C20H19ClN4O4S/c1-10-2-3-11(6-14(10)21)23-20(29)22-7-16-12-8-25(19(28)13(12)9-30-16)15-4-5-17(26)24-18(15)27/h2-3,6,9,15H,4-5,7-8H2,1H3,(H2,22,23,29)(H,24,26,27)",UIJJBTOFEJMPCM-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,GSPT1;eRF1;CK1α;c-Myc,,G-loop_beta-hairpin,IRF4,,CRBN,Q96SW2,"Cell: H929; IC50 = 1.45 ± 0.60 nM; 
Cell: MM1.S; IC50 = 1.65 ± 0.34 nM; 
Cell: RPMI 8226; IC50 = 1.21 ± 0.34 nM; 
Cell: KAS-6/1; IC50 = 5.89 ± 0.46 nM; ",,,,,,https://doi.org/10.1007/s00109-020-01943-6,,,,C20H19ClN4O4S,446.92,446.0816,2.79,-4.42,107.61,8,3,4,4,2,2,2,1,30,10,0,0
1310,O=C1CCC(N2CC3=CC(NC(=O)C4=NC5=CC=CC=C5N4)=CC=C3C2=O)C(=O)N1,16,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-1H-benzimidazole-2-carboxamide","InChI=1S/C21H17N5O4/c27-17-8-7-16(19(28)25-17)26-10-11-9-12(5-6-13(11)21(26)30)22-20(29)18-23-14-3-1-2-4-15(14)24-18/h1-6,9,16H,7-8,10H2,(H,22,29)(H,23,24)(H,25,27,28)",CSFMNDABCGEUMH-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 11.1 ± 0.7 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C21H17N5O4,403.40,403.1281,1.58,-3.82,124.26,9,3,3,5,2,3,2,1,30,9,0,0
1311,O=C1CCC(N2CC3=CC(NC(=O)C4=CN5C=CC=C(C(F)(F)F)C5=N4)=CC=C3C2=O)C(=O)N1,28,"N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-8-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide","InChI=1S/C22H16F3N5O4/c23-22(24,25)14-2-1-7-29-10-15(27-18(14)29)19(32)26-12-3-4-13-11(8-12)9-30(21(13)34)16-5-6-17(31)28-20(16)33/h1-4,7-8,10,16H,5-6,9H2,(H,26,32)(H,28,31,33)",DVTLHKDLOXQIAR-UHFFFAOYSA-N,Glutarimide,LenalidomideType,Discovery,,,,,,,,1,non-covalent,CK1α,CK1α MOLT-4: DC50 = 1.6 ± 1 nM,G-loop_beta-hairpin,,,CRBN,Q96SW2,MOLM-13: IC50 = 23 nM,,,,,,https://doi.org/10.1021/acs.jmedchem.4c02415,,,,C22H16F3N5O4,471.40,471.1154,2.37,-4.64,112.88,9,2,3,5,2,3,2,2,34,12,0,0
1496,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5C=CNC5=N4)=CC=C3C2=O)C(=O)N1,5,,"InChI=1S/C25H25N5O3/c31-22-6-5-21(24(32)28-22)30-14-16-11-15(3-4-19(16)25(30)33)20-12-17(13-29-9-1-2-10-29)18-7-8-26-23(18)27-20/h3-4,7-8,11-12,21H,1-2,5-6,9-10,13-14H2,(H,26,27)(H,28,31,32)",SNZGVVSAMPFNLQ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α;SALL4,"IKZF2 (DC50 = 1.5 nM, Dmax = 91 %)
SALL4 (DC50 = 9.3 nM,Dmax = 73 %)
CK1α (DC50 = 4.8 nM,Dmax = 65 %)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H25N5O3,443.51,443.1957,2.59,-4.72,98.40,8,2,4,6,3,3,3,2,33,8,0,0
1497,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5NN=CC5=N4)=CC=C3C2=O)C(=O)N1,6,,"InChI=1S/C24H24N6O3/c31-21-6-5-20(23(32)27-21)30-13-15-9-14(3-4-17(15)24(30)33)18-10-16(12-29-7-1-2-8-29)22-19(26-18)11-25-28-22/h3-4,9-11,20H,1-2,5-8,12-13H2,(H,25,28)(H,27,31,32)",FWYWLVJGQNRTAP-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 2.0 nM, Dmax = 90%)
CK1α (DC50 = 2.3 nM, Dmax = 89%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C24H24N6O3,444.50,444.1910,1.98,-4.16,111.29,9,2,4,6,3,3,3,2,33,9,0,0
1498,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5NN=C(C(F)(F)F)C5=N4)=CC=C3C2=O)C(=O)N1,7,,"InChI=1S/C25H23F3N6O3/c26-25(27,28)22-21-20(31-32-22)15(11-33-7-1-2-8-33)10-17(29-21)13-3-4-16-14(9-13)12-34(24(16)37)18-5-6-19(35)30-23(18)36/h3-4,9-10,18H,1-2,5-8,11-12H2,(H,31,32)(H,30,35,36)",FJMVTNGVNVQTKX-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 6.2 nM, Dmax = 86%) CK1α (DC50 = 0.9 nM, Dmax = 95%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H23F3N6O3,512.49,512.1784,3.00,-5.35,111.29,9,2,4,6,3,3,3,2,37,12,0,0
1499,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5NN=C(C6CC6)C5=N4)=CC=C3C2=O)C(=O)N1,8,,"InChI=1S/C27H28N6O3/c34-22-8-7-21(26(35)29-22)33-14-17-11-16(5-6-19(17)27(33)36)20-12-18(13-32-9-1-2-10-32)24-25(28-20)23(30-31-24)15-3-4-15/h5-6,11-12,15,21H,1-4,7-10,13-14H2,(H,30,31)(H,29,34,35)",BXYIZAXLXHKKNJ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 1.2 nM, Dmax = 85%) CK1α (DC50 = 2.2 nM, Dmax = 82%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H28N6O3,484.56,484.2223,2.86,-4.97,111.29,9,2,5,7,4,3,3,2,36,9,0,0
1500,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5NN=C(C6CCC6)C5=N4)=CC=C3C2=O)C(=O)N1,9,,"InChI=1S/C28H30N6O3/c35-23-9-8-22(27(36)30-23)34-15-18-12-17(6-7-20(18)28(34)37)21-13-19(14-33-10-1-2-11-33)25-26(29-21)24(31-32-25)16-4-3-5-16/h6-7,12-13,16,22H,1-5,8-11,14-15H2,(H,31,32)(H,30,35,36)",JOKANKSPKROVOJ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 0.7 nM, Dmax = 72%) CK1α (DC50 = 4.4 nM, Dmax = 59%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C28H30N6O3,498.59,498.2379,3.25,-5.33,111.29,9,2,5,7,4,3,3,2,37,9,0,0
1501,COC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,10,,"InChI=1S/C25H26N6O4/c1-35-24-22-21(28-29-24)16(12-30-8-2-3-9-30)11-18(26-22)14-4-5-17-15(10-14)13-31(25(17)34)19-6-7-20(32)27-23(19)33/h4-5,10-11,19H,2-3,6-9,12-13H2,1H3,(H,28,29)(H,27,32,33)",BFUJTJQIZGRPQG-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 1.3 nM, Dmax = 69%) CK1α (DC50 = 1.1 nM, Dmax = 86%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H26N6O4,474.52,474.2016,1.99,-4.17,120.52,10,2,5,6,3,3,3,2,35,10,0,0
1502,CC(C)OC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,11,,"InChI=1S/C27H30N6O4/c1-15(2)37-26-24-23(30-31-26)18(13-32-9-3-4-10-32)12-20(28-24)16-5-6-19-17(11-16)14-33(27(19)36)21-7-8-22(34)29-25(21)35/h5-6,11-12,15,21H,3-4,7-10,13-14H2,1-2H3,(H,30,31)(H,29,34,35)",FUEARKGXPYVLDT-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 0.4 nM, Dmax = 69%) CK1α (DC50 = 0.9 nM, Dmax = 82%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H30N6O4,502.58,502.2329,2.77,-4.85,120.52,10,2,6,6,3,3,3,2,37,10,0,0
1503,NC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,12,,"InChI=1S/C24H25N7O3/c25-22-21-20(28-29-22)15(11-30-7-1-2-8-30)10-17(26-21)13-3-4-16-14(9-13)12-31(24(16)34)18-5-6-19(32)27-23(18)33/h3-4,9-10,18H,1-2,5-8,11-12H2,(H3,25,28,29)(H,27,32,33)",HUZLPHWJLUUHAZ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 7.7 nM, Dmax = 89%) CK1α (DC50 = 160 nM, Dmax = 49%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C24H25N7O3,459.51,459.2019,1.56,-3.59,137.31,10,4,4,6,3,3,3,2,34,10,0,0
1504,NC1=NNC2=C(CN3CCC(F)C3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,13,,"InChI=1S/C24H24FN7O3/c25-15-5-6-31(11-15)9-14-8-17(27-21-20(14)29-30-22(21)26)12-1-2-16-13(7-12)10-32(24(16)35)18-3-4-19(33)28-23(18)34/h1-2,7-8,15,18H,3-6,9-11H2,(H3,26,29,30)(H,28,33,34)",YOTWCLAQZCFKKS-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 36 nM, Dmax = 75%) CK1α (DC50 = 130 nM, Dmax = 24%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C24H24FN7O3,477.50,477.1925,1.51,-3.66,137.31,10,4,4,6,3,3,3,2,35,11,0,0
1505,NC1=NNC2=C(CN3CCC(O)C3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,14,,"InChI=1S/C24H25N7O4/c25-22-21-20(28-29-22)14(9-30-6-5-15(32)11-30)8-17(26-21)12-1-2-16-13(7-12)10-31(24(16)35)18-3-4-19(33)27-23(18)34/h1-2,7-8,15,18,32H,3-6,9-11H2,(H3,25,28,29)(H,27,33,34)",CCSLZJTUKMSIHD-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α," IKZF2 (DC50 = 320 nM, Dmax = 55%) CK1α (DC50 = nt, Dmax = nt)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C24H25N7O4,475.51,475.1968,0.53,-2.95,157.54,11,5,4,6,3,3,3,2,35,11,0,0
1506,NC1=NNC2=C(CN3CCC(F)CC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,15,,"InChI=1S/C25H26FN7O3/c26-16-5-7-32(8-6-16)11-15-10-18(28-22-21(15)30-31-23(22)27)13-1-2-17-14(9-13)12-33(25(17)36)19-3-4-20(34)29-24(19)35/h1-2,9-10,16,19H,3-8,11-12H2,(H3,27,30,31)(H,29,34,35)",MXZUZNYXSXERNT-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 5.8 nM, Dmax = 77%) CK1α (DC50 = 270 nM, Dmax = 52%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H26FN7O3,491.53,491.2081,1.90,-4.02,137.31,10,4,4,6,3,3,3,2,36,11,0,0
1507,NC1=NNC2=C(CN3CCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,16,,"InChI=1S/C23H23N7O3/c24-21-20-19(27-28-21)14(10-29-6-1-7-29)9-16(25-20)12-2-3-15-13(8-12)11-30(23(15)33)17-4-5-18(31)26-22(17)32/h2-3,8-9,17H,1,4-7,10-11H2,(H3,24,27,28)(H,26,31,32)",LAXPQGCLPHSTCP-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 170 nM, Dmax = 67%) CK1α (DC50 = 10,000 nM, Dmax = 19%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C23H23N7O3,445.48,445.1862,1.17,-3.23,137.31,10,4,4,6,3,3,3,2,33,10,0,0
1508,NC1=NNC2=C(CN3CC(F)C3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,17,,"InChI=1S/C23H22FN7O3/c24-14-9-30(10-14)7-13-6-16(26-20-19(13)28-29-21(20)25)11-1-2-15-12(5-11)8-31(23(15)34)17-3-4-18(32)27-22(17)33/h1-2,5-6,14,17H,3-4,7-10H2,(H3,25,28,29)(H,27,32,33)",WCTPVKHFNNKOTD-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 74 nM, Dmax = 63%) CK1α (DC50 = 790 nM, Dmax = 23%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C23H22FN7O3,463.47,463.1768,1.12,-3.30,137.31,10,4,4,6,3,3,3,2,34,11,0,0
1509,NC1=NNC2=C(CN3CC4COCC(C4)C3)C=C(C3=CC4=C(C=C3)C(=O)N(C3CCC(=O)NC3=O)C4)N=C12,18,,"InChI=1S/C27H29N7O4/c28-25-24-23(31-32-25)18(10-33-8-14-5-15(9-33)13-38-12-14)7-20(29-24)16-1-2-19-17(6-16)11-34(27(19)37)21-3-4-22(35)30-26(21)36/h1-2,6-7,14-15,21H,3-5,8-13H2,(H3,28,31,32)(H,30,35,36)",WWOHNLWDCHDZDG-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 12 nM, Dmax = 81%) CK1α (DC50 = 99 nM, Dmax = 48%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H29N7O4,515.57,515.2281,1.44,-3.80,146.54,11,4,4,7,4,3,4,2,38,11,0,2
1510,NC1=NNC2=C(CN3CC4COCC4C3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,19,,"InChI=1S/C26H27N7O4/c27-24-23-22(30-31-24)15(7-32-8-16-11-37-12-17(16)9-32)6-19(28-23)13-1-2-18-14(5-13)10-33(26(18)36)20-3-4-21(34)29-25(20)35/h1-2,5-6,16-17,20H,3-4,7-12H2,(H3,27,30,31)(H,29,34,35)",JDLIGRQSRGPCHF-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α," IKZF2 (DC50 = 110 nM, Dmax = 65%) CK1α (DC50 = 750 nM, Dmax = 46%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C26H27N7O4,501.55,501.2125,1.05,-3.37,146.54,11,4,4,7,4,3,4,2,37,11,0,0
1511,NC1=NNC2=C(CN3CCCC4(COC4)C3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,20,,"InChI=1S/C27H29N7O4/c28-24-23-22(31-32-24)17(10-33-7-1-6-27(12-33)13-38-14-27)9-19(29-23)15-2-3-18-16(8-15)11-34(26(18)37)20-4-5-21(35)30-25(20)36/h2-3,8-9,20H,1,4-7,10-14H2,(H3,28,31,32)(H,30,35,36)",IZSDNUFXBLBMLW-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 43 nM, Dmax = 71%) CK1α (DC50 = 730 nM, Dmax = 38%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H29N7O4,515.57,515.2281,1.58,-3.90,146.54,11,4,4,7,4,3,4,2,38,11,1,0
1512,CN1N=C(N)C2=NC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=CC(CN3CCCC3)=C21,21,,"InChI=1S/C25H27N7O3/c1-30-22-16(12-31-8-2-3-9-31)11-18(27-21(22)23(26)29-30)14-4-5-17-15(10-14)13-32(25(17)35)19-6-7-20(33)28-24(19)34/h4-5,10-11,19H,2-3,6-9,12-13H2,1H3,(H2,26,29)(H,28,33,34)",RIRKNMJJINDXAY-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 3.3 nM, Dmax = 88%) CK1α (DC50 = 14 nM, Dmax = 54%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H27N7O3,473.54,473.2175,1.57,-3.51,126.45,10,3,4,6,3,3,3,2,35,10,0,0
1513,CCN1N=C(N)C2=NC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=CC(CN3CCCC3)=C21,22,,"InChI=1S/C26H29N7O3/c1-2-33-23-17(13-31-9-3-4-10-31)12-19(28-22(23)24(27)30-33)15-5-6-18-16(11-15)14-32(26(18)36)20-7-8-21(34)29-25(20)35/h5-6,11-12,20H,2-4,7-10,13-14H2,1H3,(H2,27,30)(H,29,34,35)",DNDGIEAVKFHOMQ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α," IKZF2 (DC50 = 6.1 nM, Dmax = 78%) CK1α (DC50 = 21 nM, Dmax = 65%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C26H29N7O3,487.56,487.2332,2.06,-3.89,126.45,10,3,5,6,3,3,3,2,36,10,0,0
1514,CC(C)N1N=C(N)C2=NC(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)=CC(CN3CCCC3)=C21,23,,"InChI=1S/C27H31N7O3/c1-15(2)34-24-18(13-32-9-3-4-10-32)12-20(29-23(24)25(28)31-34)16-5-6-19-17(11-16)14-33(27(19)37)21-7-8-22(35)30-26(21)36/h5-6,11-12,15,21H,3-4,7-10,13-14H2,1-2H3,(H2,28,31)(H,30,35,36)",GIPDBGRBDCKLCK-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 16 nM, Dmax = 73%) CK1α (DC50 = 10 nM, Dmax = 78%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H31N7O3,501.59,501.2488,2.62,-4.38,126.45,10,3,5,6,3,3,3,2,37,10,0,0
1515,NC1=NN(C2CC2)C2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,24,,"InChI=1S/C27H29N7O3/c28-25-23-24(34(31-25)18-4-5-18)17(13-32-9-1-2-10-32)12-20(29-23)15-3-6-19-16(11-15)14-33(27(19)37)21-7-8-22(35)30-26(21)36/h3,6,11-12,18,21H,1-2,4-5,7-10,13-14H2,(H2,28,31)(H,30,35,36)",XTOJEKXWALNRFH-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 2.0 nM, Dmax = 83%) CK1α (DC50 = 25 nM, Dmax = 74%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H29N7O3,499.58,499.2332,2.37,-4.18,126.45,10,3,5,7,4,3,3,2,37,10,0,0
1516,NC1=NN(C2COC2)C2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,25,,"InChI=1S/C27H29N7O4/c28-25-23-24(34(31-25)18-13-38-14-18)17(11-32-7-1-2-8-32)10-20(29-23)15-3-4-19-16(9-15)12-33(27(19)37)21-5-6-22(35)30-26(21)36/h3-4,9-10,18,21H,1-2,5-8,11-14H2,(H2,28,31)(H,30,35,36)",NRSXGRIVVGXVRK-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 31 nM, Dmax = 63%) CK1α (DC50 = 540 nM, Dmax = 47%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H29N7O4,515.57,515.2281,1.61,-3.71,135.68,11,3,5,7,4,3,4,2,38,11,0,0
1517,CNC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,26,,"InChI=1S/C25H27N7O3/c1-26-23-22-21(29-30-23)16(12-31-8-2-3-9-31)11-18(27-22)14-4-5-17-15(10-14)13-32(25(17)35)19-6-7-20(33)28-24(19)34/h4-5,10-11,19H,2-3,6-9,12-13H2,1H3,(H2,26,29,30)(H,28,33,34)",UQQRGWMKCDTJPQ-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α," IKZF2 (DC50 = 2.5 nM, Dmax = 87%) CK1α (DC50 = 31 nM, Dmax = 26%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C25H27N7O3,473.54,473.2175,2.02,-4.05,123.32,10,3,5,6,3,3,3,2,35,10,0,0
1518,CCNC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,27,,"InChI=1S/C26H29N7O3/c1-2-27-24-23-22(30-31-24)17(13-32-9-3-4-10-32)12-19(28-23)15-5-6-18-16(11-15)14-33(26(18)36)20-7-8-21(34)29-25(20)35/h5-6,11-12,20H,2-4,7-10,13-14H2,1H3,(H2,27,30,31)(H,29,34,35)",FTYJOMFRHLNFGD-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 3.8 nM, Dmax = 87%) CK1α (DC50 = >10,000 nM, Dmax = 11%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C26H29N7O3,487.56,487.2332,2.41,-4.66,123.32,10,3,6,6,3,3,3,2,36,10,0,0
1519,CC(C)NC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,28,,"InChI=1S/C27H31N7O3/c1-15(2)28-25-24-23(31-32-25)18(13-33-9-3-4-10-33)12-20(29-24)16-5-6-19-17(11-16)14-34(27(19)37)21-7-8-22(35)30-26(21)36/h5-6,11-12,15,21H,3-4,7-10,13-14H2,1-2H3,(H2,28,31,32)(H,30,35,36)",ZEGBRJSQYXZREI-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 2.8 nM, Dmax = 87%) CK1α (DC50 = >10,000 nM, Dmax = 15%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H31N7O3,501.59,501.2488,2.80,-5.03,123.32,10,3,6,6,3,3,3,2,37,10,0,0
1520,O=C1CCC(N2CC3=CC(C4=CC(CN5CCCC5)=C5NN=C(NC6COC6)C5=N4)=CC=C3C2=O)C(=O)N1,29,,"InChI=1S/C27H29N7O4/c35-22-6-5-21(26(36)30-22)34-12-16-9-15(3-4-19(16)27(34)37)20-10-17(11-33-7-1-2-8-33)23-24(29-20)25(32-31-23)28-18-13-38-14-18/h3-4,9-10,18,21H,1-2,5-8,11-14H2,(H2,28,31,32)(H,30,35,36)",MCNVRDRTTNAXGD-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = >10,000 nM, Dmax = 15%) CK1α (DC50 = >10,000 nM, Dmax = 9%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H29N7O4,515.57,515.2281,1.79,-4.36,132.55,11,3,6,7,4,3,4,2,38,11,0,0
1521,CN(C)C1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)N=C12,30,,"InChI=1S/C26H29N7O3/c1-31(2)24-23-22(29-30-24)17(13-32-9-3-4-10-32)12-19(27-23)15-5-6-18-16(11-15)14-33(26(18)36)20-7-8-21(34)28-25(20)35/h5-6,11-12,20H,3-4,7-10,13-14H2,1-2H3,(H,29,30)(H,28,34,35)",AGNJJBASPCXFPI-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 0.5 nM, Dmax = 84%) CK1α (DC50 = 1.7 nM, Dmax = 79%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C26H29N7O3,487.56,487.2332,2.05,-4.20,114.53,10,2,5,6,3,3,3,2,36,10,0,0
1522,CC(C)NC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3F)N=C12,31,,"InChI=1S/C27H30FN7O3/c1-14(2)29-25-24-23(32-33-25)15(12-34-9-3-4-10-34)11-19(30-24)17-6-5-16-18(22(17)28)13-35(27(16)38)20-7-8-21(36)31-26(20)37/h5-6,11,14,20H,3-4,7-10,12-13H2,1-2H3,(H2,29,32,33)(H,31,36,37)",ZYMWJRANZLPARA-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 0.6 nM, Dmax = 86%) CK1α (DC50 = 210 nM, Dmax = 23%)",Unknown,,,CRBN,Q96SW2,,,,,,"PK profile of 31 in micea.  IV dose (mg/kg)b 1  T1/2 (h) 3.0 CL (mL/min/kg) 103 Vss (L/kg) 1.26  PO dose (mg/kg)c 3 T1/2 (h) 2.8 Cmax (ng/mL) 60 AUC (h*ng/mL) 101 F (%) 22  a CD-1 mouse, n = 3; bIV formulation: 5 %  DMSO+10 %solutol+85 %saline cPO.formulation: 5 %DMSO+10 %solutol+85 %water.",https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H30FN7O3,519.58,519.2394,2.94,-5.33,123.32,10,3,6,6,3,3,3,2,38,11,0,0
1523,CC(C)NC1=NNC2=C(CN3CCCC3)C=C(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3Cl)N=C12,32,,"InChI=1S/C27H30ClN7O3/c1-14(2)29-25-24-23(32-33-25)15(12-34-9-3-4-10-34)11-19(30-24)17-6-5-16-18(22(17)28)13-35(27(16)38)20-7-8-21(36)31-26(20)37/h5-6,11,14,20H,3-4,7-10,12-13H2,1-2H3,(H2,29,32,33)(H,31,36,37)",FBVLNDYWKXSEJE-UHFFFAOYSA-N,Glutarimide,Non-domideType,Discovery,,,,,,,,1,non-covalent,IKZF2;CK1α,"IKZF2 (DC50 = 3.7 nM, Dmax = 64%) CK1α (DC50 = >10,000 nM, Dmax = 20%)",Unknown,,,CRBN,Q96SW2,,,,,,,https://doi.org/10.1016/j.bmcl.2025.130263,,,,C27H30ClN7O3,536.04,535.2099,3.46,-5.87,123.32,10,3,6,6,3,3,3,2,38,11,0,0